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Alzheimer’s dementia is a chronic degenerative disease characterized by a
slow and progressive neuronal degeneration that damages and eventually
destroys brain cells, leading to memory loss and changes in thinking and
other brain functions. It usually develops slowly and gradually gets worse
as more brain cells wither and die. Eventually, Alzheimer’s is fatal, and
currently, there is no cure [1]. It is the most common type of dementia
and, due to the aging of the population, continuously increasing. Because
of this, it is one of the most signi￿cant "emergencies" that the health and
social systems are facing, also because of the number of years in which this
disease burden on the welfare services and families. The data regarding the
prevalence of dementia reported in studies conducted in several industrialized
countries, indicate comparable rates, hovering around 5% in subjects older
than 65 years old.
There isn’t a well-demarcated border between normality and disease,
rather a kind of transition. The main di￿culty is to identify the onset, that it
could happen several years before ￿rst symptoms appear. Therefore, one of
the main challenges today is to be able to diagnose in the very early stage the
Alzheimer’s disease, even before the emergence of signi￿cant memory prob-
lems. This provides an opportunity for possible new therapeutic approaches
that may alter the underlying disease process and have the potential to slow
down or stop the progression of the disease.
Degeneration of the cortical cholinergic system is one of the most consis-
tent neurochemical changes in degenerative diseases like Alzheimer disease
(AD) [2]. The cholinergic system and its components, above all Acetyl-
choline, a brain neurotransmitter involved in cholinergic transmission, and
the 2 enzymes that degrade it, acetylcholinesterase (AChE) and butyryl-
cholinesterase (BuChE) become, more often, object of study, in order to
investigate any de￿cit which might be symptomatic of an eventual dementia.
During the last two decades, N-methylpiperidinyl esters have been exten-
sively characterized as synthetic substrates for AChE [3] while, until recently,
the role of BuChE has been largely ignored. However, increasing evidence
supports the role of BuChE in the pathophysiology of AD. In severe AD,
in fact, the level of AChE is decreased by as much as 90% compared with
normal values, whereas the level of BuChE increases by approximately 30%.
In such cases, BuChE may be a more appropriate therapeutic target [4], [5].4
1-11C-Methyl-4-piperidinyl n-butyrate (11C-MP4B), is a new radiophar-
maceutical for the in vivo assessment of BuChE activity using PET [6]. It
is the ￿rst radioligand validated for the study of BuChE activity in human
brain. It is the speci￿c substrate for BuChE and is inert for AChE. PET can
be applied to detect cholinergic de￿cits at an early stage of a dementing dis-
ease and also to study the e￿ect of cholinesterase (ChE) inhibitors or other
cholinergic drugs in vivo [7].
PET quanti￿cation consists of an estimate of the kinetics coe￿cients us-
ing the relationship between the data of the tissue measured through the
scanner PET and the input function, typically extracted from arterial sam-
pling corrected for metabolites [8], [9]. This method is based on the assump-
tion that there is a known and validated model for the tracer from which it is
possible to start the estimation process. One of the purpose of this work is to
develop a compartmental model for the 11C-MP4B since , to our knowledge,
no model for this tracer has been developed yet.
Quanti￿cation can be done either by averaging time-activity curves (TAC)
on functionally de￿ned regions of interest (ROIs) and/or at voxel level using
a tracer kinetic model structure. At ROI level, TACs are characterized by a
good signal-to-noise ratio (SNR). In general, the number of regions to be an-
alyzed is limited, so the state of art would expect using non linear estimators.
However, the ROI analysis leads to a loss of the original spatial resolution.
Voxel level analysis solves the model for each element of the image producing
parametric maps having the same spatial resolution as the original PET im-
age. Due to the low SNR of the voxel kinetics and very high number of voxels
to be analyzed, nonlinear estimators cannot be used and faster algorithms
are needed.
The other purpose of this work is then to quantify cholinergic activ-
ity, previously through a ROI-level analysis, where images were partitioned
through a functional clustering based on parametrization of Time Activity
Curves, and then through voxel-level analysis. In order to lighten the bur-
den of the method and obtained precise estimates we used Basis Functions
Method estimation (BFMs) (Gunn et al., 1997; Hong and Fryer, 2010; Hong
et al., 2011) and Bayesian estimation (Zhou et al., 2002; Alpert and Yuan,




Alzheimer’s disease is a pathology that, to be identi￿ed, diagnosed, treated
and managed, it must be known. In this ￿rst chapter we try to de￿ne what
are the characteristics of this disease, to indicate who and what a￿ects, to
describe symptoms and course and to give an overview of what are the current
methods of therapies.
2.1 Alzheimer’s disease
Alzheimer’s disease (AD), also known in medical literature as Alzheimer dis-
ease, is the most common disabling degenerative senile dementia, it was ￿rst
described by German psychiatrist and neuro-pathologist Alois Alzheimer in
1906 and was named after him. Current therapies for the treatment or the
incisive slowing of the disease are not e￿ective enough and the progression
of symptoms leads inevitably to death within ten years. The problem of
the limited and not conclusive e￿ectiveness of available therapies , combined
with its wide and growing spread in the population and the enormous re-
sources required for its management (social, emotional, organizational and
economic), which fall largely on family members of patients, make of the
Alzheimer’s Disease one of the most serious diseases with a social impact in
the world.
2.1.1 Epidemiology and economics
Economically speaking, the Alzheimer’s disease is undoubtedly an interest-
ing disease. Statistics say that about 5% of people over age 65 su￿er from
Alzheimer’s and, except for a reduced percentage of individuals a￿ected in
young age, in over 95% of cases, people are a￿ected by this neuro-degenerative
disorder in elderly age. The same statistics tell us that the average age of
the population is rapidly increasing thus expanding the number of potential
patients and, as a result, potential users of medication to treat the disease.
It is useless to deny that scienti￿c research and economics are intertwined
issues.6 2.1 Alzheimer’s disease
The determination of the social cost of Alzheimer’s disease involves the
analysis of all the costs incurred for the care and assistance of the sick ,that
may come not only from the sick and his family, but also from health service,
and the analysis of the impact of the disease in the community in general.
Care, assistance, supervision to a person with Alzheimer’s require, in fact, a
consisting series of expenses , some costs can be directly quanti￿able for the
purchase of goods and services (direct costs), some not, and they represent
the indirect costs related to the disease. These, which do not provide a real
expenditure, are evaluated using the concept of opportunity cost, considering
the alternative use of time that the person could have done and applying to
this time an economic value. Indirect costs are therefore the result of a loss of
resources for the community associated with the disease, especially in terms
of time taken to any production activity that a￿ects both the patient and the
caregiver involved in assistance. In addition, in the calculation of indirect
costs, we can insert also that of informal care given by family members,
calculated by estimating the costs that would have been needed to support,
in case of employment of paid sta￿.
From the reports of the association of Alzheimer’s Disease International,
2009, it was estimated at 36 million the number of people worldwide su￿ering
from dementia. This number is expected to double every 20 years, reaching 66
million in 2030 and 115 in 2050. Worldwide spending on dementia (604 billion
U.S. dollars in 2010) amounts to more than 1% of global GDP, according to
the 2010 Report, if spending on dementia was a national budget, would be
18th among the richest countries in the world.
In particular, in the European Community, based on UN’s demographic
forecast combined with Eurocode’s new prevalence ￿gures for Europe, it has
been estimated that the number of demented will increase considerably from
about 10 million today to about 14 million demented persons in 2030 (Figure
2.1). The relative cost prognosis is seen in Figure 2.1. The demographic
forecast of costs will result in an increase in the whole Europe by about 43%
between 2008 and 2030 to over 250 billions euros [1].
In addition to large economic interests at stake, the possibility of de-
feating a disease that can a￿ect all, highly debilitating and extremely high
social costs, pushes many research groups around the world to study how this
disease born, progresses, attacks the cells of our brain and destroys them.
2.1.2 Pathophysiology
Alzheimer’s disease is a disease of the central nervous system characterized
by the progressive and relentless cell death of neurons belonging to the asso-
ciation areas of the cerebral cortex.
The onset of Alzheimer’s disease is sneaky and insidious, often hardly
recognizable even to those who are closest to the patient. It is characterized
by the appearance of non-cognitive symptoms: depression, social withdrawal,
a￿ective ￿attening, low interest rates, neglect of the person, often delusional
ideas of persecution or reference, anxiety. Usual associated memory disor-
ders are de￿cits in learning new information, di￿culty in remembering taken
commitments and ￿rst occurred events.
The short-term memory, working tool needed to learn new information
and retrieve memory traces, is the ￿rst to undergo to a de￿cit, causing dis-2.1 Alzheimer’s disease 7
Figure 2.1: Prognosis for the number of demented and future costs of dementia in
Europe until 2030.
comfort to the individual and his family. The Episodic memory, which con-
tains information about episodes or events and their space-time relations,
is the ￿rst to fall, crumbling gradually the many episodes that have estab-
lished the identity of the person, leading to insecurity and hesitancy. As the
disease progresses sicks loose also the memory semantics, wealth of general
knowledge: words,symbols, rules, formulas.
The 99% of cases of Alzheimer’s disease is "sporadic", that means it oc-
curs in people who do not have a clear familiarity and only 1% of cases of
Alzheimer’s disease is caused by an altered gene that determines the trans-
mission from one generation to another. The cause of both sporadic cases
and those family seems to lie in an alteration in the metabolism of a pro-
tein called APP (amyloid beta protein precursor) and for unknown reasons
at a certain time of life it begins to be altered metabolized, leading to the
formation of a neurotoxic substance (precisely the beta amyloid) that slowly
accumulates in the brain leading to progressive neuronal death [10].
The accumulation of beta amyloid seems to start decades before the typ-
ical disorders of memory, from the appearance of which, within a few years,
more and more disabling di￿culties occur in the management of activities of
daily living, until the total loss of self. In patients with Alzheimer’s disease
there is a loss of nerve cells in areas of the brain vital to memory and other
cognitive functions (Figure 2.2). Today, the plaques formed by amyloid pro-
teins and tangles are considered the e￿ects on nerve tissue of a disease of
which, despite the considerable e￿orts made in the ￿eld, we still do not know
the causes.
In the mid-70s it was discovered that in people with Alzheimer’s disease
the levels of the neurotransmitter acetylcholine were much lower than nor-
mal. The discovery was interesting for several reasons, ￿rst of all it ￿nally
connected Alzheimer’s disease with the biochemical changes in the brain.
Acetylcholine is a neurotransmitter of crucial importance in the process of8 2.2 Cholinergic System
Figure 2.2: Brain areas involved in Alzheimer’s disease degeneration.
memory formation, in addition to being the one commonly used by neurons
in the hippocampus and cerebral cortex, areas most damaged by the disease.
After this discovery, acetylcholine has been the subject of hundreds of stud-
ies. The levels of acetylcholine are reduced slightly in all older people, but
in people with Alzheimer’s, they are reduced since 90%. People with more
severe memory disorders show the major de￿ciency of acetylcholine. These
discoveries have led to the hope that compensate the lack of acetylcholine
with the use of drugs is a possible treatment for dementia [11].
2.2 Cholinergic System
The cholinergic system is a system of nerve cells that uses acetylcholine in
transmitting nerve impulse. Impairment of cholinergic neuro-transmission
in the central nervous system leads to severe cognitive disorders. The brain
contains a network of cholinergic neurons , those with cell bodies in the basal
forebrain project to areas of the brain linked with cognitive function, memory
and learning (Figure 2.3).
Figure 2.3: The medial septal nuclei and basal nucleus of Meynert project widely
upon the cerebral cortex, including the hippocampus. The pontomes-
encephalotegmental complex projects to the thalamus and parts of the
forebrain
Degeneration of neurons in the cholinergic system occurs in Alzheimer’s2.2 Cholinergic System 9
disease and this may contribute to impaired cognitive function and learning,
characteristics of the disease. Acetylcholine is an important neurotransmitter
in both the peripheral nervous system (PNS: skeletal and smooth muscle,
autonomic sympathetic and parasympathetic ganglia), and in the central
nervous system (CNS) and, as recently discovered, has a fundamental role
in the evolution of the disease. In the next paragraphs we will describe
what is Acetylcholine and what is its role in the cholinergic transmission of
impulses, what are the enzymes involved in the activity of cholinergic neurons
(Acetylcholinesterase and Butyrylcholinesterase) and eventually what are the
therapies for the treatment of AD that work on the cholinergic system.
2.2.1 Acetylcholine
The chemical compound known as acetylcholine (ACh), was the ￿rst neuro-
transmitter to be identi￿ed. Acetylcholine acts as a chemical mediator on the
transmission of nerve impulses (called cholinergic transmission in this case),
in multiple points of the central (CNS) and the peripheral nervous system
(PNS) [12]. Many of the cholinergic neurons of the CNS form a large ascend-
ing system; while the bodies of these neurons are in the reticular formation,
the axons radiate to all parts of the forebrain, including the hypothalamus,
thalamus, the optic tract, the basal ganglia, the hippocampus and neocortex
(Figure 2.3).
ACh has been linked directly or indirectly with various brain functions.
More in detail, acetylcholine is secreted by the following neurons:
CNS neurons are involved in three speci￿c regions:
o neurons in the dorsolateral pons, which have numerous targets
within the CNS and are involved in REM sleep;
o neurons of the basal forebrain, the major source of cholinergic
innervation of cortical origin, involved in learning;
o neurons of the medial region of the pellucid septum, which projects
its axons mainly to the limbic system;
o many interneurons of the basal ganglia;
PNS ’s involved neurons are:
o somatic motor neurons, causing the contraction of skeletal muscle;
o or the neurons of the autonomic nervous system:
- neurons pre-and post-ganglionic of the parasympathetic ner-
vous system;
- pre-ganglionic neurons of the sympathetic nervous system;
Neurochemistry of Acetylcholine relates to its biosynthesis, deposit, re-
lease and metabolism. These processes are summarize in Figure 2.4.10 2.2 Cholinergic System
Figure 2.4: Acetylcholine is made from choline and acetyl CoA, then is rapidly
broken down by the enzyme acetylcholinesterase in the synaptic cleft.
Choline is transported back into the axon terminal and is used to make
more ACh.
Biosynthesis
Acetylcholine (often abbreviated ACh) is an organic, polyatomic cation; it is
an ester of acetic acid and choline, with chemical formula CH3COO(CH2)2N +(CH3).
Acetylcholine is synthesized from its two immediate precursors, choline (Ch)
and acetyl coenzyme A (ACoA). The synthesis reaction is a single step cat-
alyzed by choline acetyltransferase (ChAT), an enzyme synthesized in the
cholinergic neuron.
Choline + Acetyl coenzyme A
ChAT

 Acetylcholine + Coenzyme A
Part of the choline is synthesized from the amino acid Serine but the
major part comes from the recycle subsequently the enzymatic hydrolysis
in the synaptic space. Extracellular choline is actively transferred in the
presynaptic nervous terminal from high and low a￿nity reuptake system.
High a￿nity sites are responsible of the most part of the choline recycled by
the synapsis and used for the biosynthesis of the neurotransmitter[13] [12].
The reuptake choline process is considered the passage that determines the
speed of the whole biosynthetic process.
Deposit
Most of the Acetylcholine just synthesized is actively transferred through the
use of cytosolic depositary vesicle located in the presynaptic nervous termi-
nal, here the ACh is preserved until its release. Part of this Acetylcholine
remains in the cytosol and it is eventually hydrolyzed in choline and acetate.
Only the Acetylcholine in the vesicles is used as a neurotransmitter.2.2 Cholinergic System 11
Release
The Acetylcholine release process from the depositary vesicles is initialized
from an action potential transmitted towards the axon up to the nervous pre-
synaptic membrane. This potential action induces the opening of the voltage
dependent calcium channels , and leads to the release of Acetylcholine in the
synapsis.
Metabolism
In the synapsis the Ach can ligate, to make a reaction, with the receptors
located on the pre-synaptic or post-synaptic membrane. Acetylcholine must
be rapidly removed from the synapsis to allow repolarization so free Ach,
not ligated with receptors, is hydrolyzed in acetate and choline. This reac-
tion is catalyzed from the Cholinesterase and this mechanism represents the
physiological way to interrupt its action. This enzyme is also called speci￿c
cholinesterase and it has his maximum a￿nity with acetylcholine but also
hydrolyzes other choline esters .
2.2.2 Acetylcholine receptors
The ACh acts using two di￿erent types of cholinergic receptors (AChR) that
are widely distributed in the whole brain. These receptors are classi￿ed as
muscarinic and nicotinic receptors. Some regions of the brain are character-
ized by the presence of the only muscarinic subtype (midbrain, medulla, and
pons), while other regions (substantia nigra, locus caeruleus and septum) by
the only nicotinic one. Both subtypes are localized in: striatum, cerebral
cortex, hippocampus, thalamus, hypothalamus and in the cerebellum. Both
muscarinic and nicotinic receptors have as endogenous ligand acetylcholine
but, historically, the di￿erentiation of the two receptor classes was made
using non-endogenous ligands: muscarine and nicotine. The muscarinic re-
ceptors, in fact, are activated (as well as by acetylcholine) also by muscarine,
but not by nicotine; nicotinic receptors instead, are activated by nicotine,
but not by muscarine, and this explains the denomination [14].
Nicotinic Receptors
The nicotinic receptors are ionotropic receptors permeable to sodium, potas-
sium, and chloride ions; they are divided into three main classes: muscle,
ganglion and the central nervous system. Ion channels are activated by lig-
and.
The muscle receptors are localized at the level of the neuromuscular junc-
tion of skeletal muscle, the ganglionic receptors are responsible for transmit-
ting at sympathetic and parasympathetic ganglia level and the receptors in
the CNS are widespread in the brain.
The nicotinic receptors, with a molecular mass of about 280 kDa, are
constituted by 5 sub-units, that are arranged symmetrically so as to circum-
scribe a pore through which occurs the ￿ow of cations (Na and Ca incoming,
outgoing K). Each subunit is composed of four transmembrane domains (Fig-
ure 2.5 ), with the N-terminal and C-terminal both on the extracellular side
[15].12 2.2 Cholinergic System
Figure 2.5: Structure of a neuronal nicotinic acetylcholine receptor (nAChR)
Currently we have identi￿ed several isoforms of the sub-units according to
the di￿erent anatomical localization of the receptors. Multiple combinations
of di￿erent types of sub-units generate di￿erent receptor subtypes. Among
various receptors, the two most important and best characterized receptor
types since today are the receptors of the neuromuscular junction and the
receptors in the CNS. Alzheimer’s disease is characterized by a reduction
in the number of nicotinic receptors, without particular di￿erences between
various subtypes.
Muscarinic Receptors
Muscarinic receptors bind both acetylcholine and muscarine, an alkaloid
present in certain poisonous mushrooms (it was ￿rst isolated in Amanita
muscaria). Cholinergic transmission (acetylcholine-mediated) that activates
muscarinic receptors occurs mainly at autonomic ganglia, organs innervated
by the parasympathetic division of the autonomic nervous system and in the
central nervous system.
All muscarinic receptors are G-protein coupled receptors. These receptors
are formed by a single sub-unit that hasn’t a directly associated channel. The
receptor comprises a polypeptide that traverses the membrane seven times,
the N-terminal is out and the C terminal is inside the cell. Inside, it contains
a binding site for the G protein, which is activated when the ACh binds to
the receptor (Figure 2.6).
Binding studies have identi￿ed ￿ve subclasses of muscarinic receptors
each one with its own locations: M1,M4 and M5 are receptors of the CNS,
M2 are the receptors of the heart and M3 are the receptors of smooth muscle.
While the nicotinic type are ligand-gated ion channels that mediate a fast
synaptic transmission of the neurotransmitter, the activation of muscarinic
receptor triggers a cascade of intracellular reactions mediated by the release2.2 Cholinergic System 13
Figure 2.6: Structure of a muscarinic nicotinic acetylcholine receptor (mAChR)
of a second messenger that mediate a slow metabolic response. Symptoms
of AD regarding muscarinic receptor, show a decrease of M2 presynaptic
receptor but not a decrease of M1 postsynaptic receptor [16].
2.2.3 Cholinesterase
In biochemistry, cholinesterase is a family of enzymes that catalyze the hy-
drolysis of the neurotransmitter acetylcholine into choline and acetic acid, a
reaction necessary to allow a cholinergic neuron to return its resting state
after activation. This family consists of two types of cholinesterase: Acetyl-
cholinesterase and Butyrylcholinesterase (also known as Pseudocholinesterase),
vertebrates possess both enzymes that probably come from the duplication
of a single gene.
Acetylcholinesterase ( AChE ), also known as RBC cholinesterase, ery-
throcyte cholinesterase, or (most formally) acetylcholine acetylhydrolase, is
a serine protease that hydrolyzes the neurotransmitter acetylcholine. AChE
has a very high catalytic activity - each molecule of AChE degrades about
25000 molecules of acetylcholine (ACh) per second, approaching the limit
allowed by di￿usion of the substrate. During neurotransmission, ACh is re-
leased from the nerve into the synaptic cleft and binds to ACh receptors
on the post-synaptic membrane, relaying the signal from the nerve. AChE,
also located on the post-synaptic membrane, terminates the signal trans-
mission by hydrolyzing ACh. The liberated choline is taken up again by
the pre-synaptic nerve and ACh is synthesized by combining with acetyl-
CoA through the action of choline acetyltransferase. For a cholinergic neu-
ron to receive another impulse, ACh must be released from the ACh re-
ceptor. This occurs only when the concentration of ACh in the synaptic
cleft is very low. Inhibition of AChE leads to accumulation of ACh in the
synaptic cleft and results in impeded neurotransmission. AChE is found
in many types of conducting tissue: nerve and muscle, central and periph-
eral tissues, motor and sensory ￿bers, and cholinergic and non-cholinergic
￿bers. Acetylcholinesterase is also found on the red blood cell membranes.
The activity of AChE is higher in motor neurons than in sensory neurons.14 2.2 Cholinergic System
Acetylcholinesterase exists in multiple molecular forms, which possess simi-
lar catalytic properties, but di￿er in their oligomeric assembly and mode of
attachment to the cell surface.
Butyrylcholinesterase ( BuChE), also known as plasma cholinesterase,
pseudocholinesterase, or (most formally) acylcholine acylhydrolase, is a non-
speci￿c cholinesterase enzyme that hydrolyses many di￿erent choline esters.
It is located in the liver, where it is synthesized and secreted in plasma, gut,
heart, kidneys and lungs. Despite the high homology with AChE,( in 539
residues h AChE and h BuChE have 52.8% identity and 69.8% homology
[4]), BuChE di￿ers in many aspect. These two enzymes are distinguished
essentially by the speci￿city of substrate: the AChE hydrolyzes the acetyl-
choline neurotransmitter more faster than the choline esters having an acyl
chain more bulky ,as the butyrylcholine. The BuChE, however, shows the
same activity toward both substrates and is, therefore, less selective. Fur-
thermore, it doesn’t show a sort of substrate inhibition but it is active only
at high substrate concentrations.
The main role of the AChE has long been known but the role of BuChE
still remains an open question, it seems that this cholinesterase has an impor-
tant role in cellular di￿erentiation and development and it was also recently
hypothesized that BuChE is not essential for survival but may play an im-
portant role, for such as "reserves" at the Ache, if it is in a condition of less
or no activity [17].
The biochemical de￿cits of AD are reduced levels of acetylcholine because
of substantial reduction in the activity of AChE, and by contrast, increased
activity of BuChE. Both AChE and BuChE, that have di￿erentiated kinetic
and molecular properties than normal neuronal forms found in the brain,
accumulate BuChE and AChE in brain can cleave >10 000 molecules of
acetylcholine per second. It is shown that AChE knockout mouse survives
for several weeks, since BuChE compensates the absence of AChE and serves
as a backup to AChE in supporting and regulating cholinergic transmission.
In a similar way, cytochemical studies have revealed that cholinergic neu-
rons contain BuChE instead of AChE, suggesting that speci￿c cholinergic
pathways are regulated by BuChE in the brain of patients with AD [17].
2.2.4 Therapies
Alzheimer disease (AD) is a chronic and progressive neurodegenerative dis-
ease that is characterized by degeneration of cholinergic neurons in the areas
of the brain particularly associated with memory, higher intellectual func-
tions and consciousness. Although other neurotransmitter systems are af-
fected, the most profound loss is that of cholinergic transmission. The possi-
ble e￿ectiveness of an intervention on the cholinergic system in symptomatic
treatment of AD, brought the research to move in di￿erent directions. A
￿rst way is intended to increase the functionality of precursors of choliner-
gic synapses by AChE precursors or by modulators of secretion and storage
of the neurotransmitter (Amino pyridine, already used in the treatment of
Multiple Sclerosis) or use of trophic factors. Another way is the one that
provides the use of direct cholinergic agents which include agonists (both2.2 Cholinergic System 15
muscarinic nicotinic) that directly stimulate receptors. Finally you can use
cholinergic agents that increase concentration of acetylcholine by inhibiting
its enzymatic hydrolysis and thereby extending the physiological function
[18].
AChE inhibitors: focus on Donepezil and Rivastigmine
Among the above pharmacological agents, AChE inhibitors seem to be the
most e￿ective method to improve cholinergic de￿cit thus reducing the symp-
toms of the disease [60]. Di￿erent types of AChE inhibitors have been stud-
ied for the treatment of AD and they di￿er in their mechanism of action,
metabolism and brain selectivity . There are four CHE-I: tacrine, galan-
tamine, donepezil and rivastigmine but only the last two are involved in our
study and we will focus on it. Cholinesterase inhibitors can be reversible,
pseudo-irreversible, or irreversible. In reversible inhibition, the inhibitor
molecule is bound to the enzyme molecule for a short period of time, af-
ter which the inhibitor and enzyme molecules dissociate and enzyme activity
is restored. In pseudo-irreversible inhibition, the inhibitor molecule binds to
the enzyme molecule, but the bond is more slowly broken down, delaying
the return of enzyme activity to normal. Irreversible inhibitors bind perma-
nently to the enzyme, and thus the enzyme does not become available again.
Donepezil is a reversible cholinesterase inhibitors. Although rivastigmine is
considered a reversible cholinesterase inhibitor, its extended interactions with
cholinesterase have been referred to as pseudo-irreversible. Cholinesterase
inhibitors can also be characterized as selective for acetylcholine-depleted ar-
eas of the central nervous system. Animal studies show that donepezil and
rivastigmine are brain selective, but there is evidence to suggest that rivastig-
mine is also brain-region selective, i.e. selective for the cerebral cortex and
hippocampus, areas mainly involved in cognitive function . There are two
types of cholinesterase that can be a￿ected by CHE-I - acetylcholinesterase
and butyrylcholinesterase. Both enzymes are present in the CNS, with bu-
tyrylcholinesterase also found in smooth and cardiac muscle, skin and serum.
Because of its presence in the periphery, a high degree of inhibition of butyryl-
cholinesterase may be associated with a greater degree of systemic cholinergic
adverse e￿ects, such as nausea and vomiting [18]. The four CHE-I di￿er in
their selectivity for acetylcholinesterase vs. butyrylcholinesterase.
Donepezil selectively inhibits acetylcholinesterase . Its elimination half-
life is approximately 70 hours. It is well absorbed and reaches peak plasma
concentrations in 3 to 4 hours. Donepezil is extensively metabolized to four
major metabolites, two of which are known to be active, and a number of
minor metabolites. A small portion of donepezil is excreted in the urine
intact.
Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.
It is rapidly absorbed after oral administration (time to maximal plasma con-
centration ranges from 0.8 to 1.2 hours). The elimination half-life of rivastig-
mine is approximately 1 hour. Renal elimination of the drug’s metabolite
is rapid and essentially complete after 24 hours. No signi￿cant drug-drug
interactions have been observed with 22 drug classes. Because rivastigmine
demonstrates low protein binding (approximately 40%), no displacement of16 2.2 Cholinergic System
other drugs is expected.
Neither food nor time of administration (morning vs evening dose) in￿u-
ences the rate or extent of absorption of donepezil. Rivastigmine is adminis-
tered with food to reduce gastrointestinal side e￿ects and improve tolerability
by delaying absorption, prolonging time to maximal plasma concentration.
In clinical trials, rivastigmine was associated with a high incidence of GI
adverse e￿ects [18].Chapter 3
PET neuroimaging for AD’s
diagnostic investigation
The recognition and diagnosis of the Alzheimer’s disease are still an open
question. Thus symptoms are undeniable just only at an advance stage, the
di￿culties lie in being able to diagnose the disease at its onset, so you can
treat it right away and be able to, if not stop, at least slow its progression.
Current diagnosis of Alzheimer’s disease is made by clinical, neuropsycholog-
ical, and neuroimaging assessments. Routine structural neuroimaging evalu-
ation is based on nonspeci￿c features such as atrophy, which is a late feature
in the progression of the disease. Therefore, developing new approaches for
early and speci￿c recognition of Alzheimer disease at the prodromal stages
is of crucial importance. In this section we will describe how a PET facility
works and what are its main features.
3.1 Positron Emission Tomography technique
Positron Emission Tomography (PET) is a nuclear medical imaging technique
that employs the electronic detection of short-lived positron-emitting radio-
pharmaceuticals (substances containing a carrier molecule, such as glucose,
and a positron-emitting radioactive isotope that labels or tags the carrier
molecule) to study and visualize human physiology [8]. The PET scanner or
camera generates three-dimensional images of the distribution of a radiophar-
maceutical administered within the body. During the scanning procedure,
doctors and researchers are able to measure in detail the functioning of the
human brain and other organs, while patients are comfortably aware and
vigilant. The generated images allow to monitor and evaluate bodily pro-
cesses such as glucose metabolism, oxygen metabolism, and cerebral blood
￿ow. New developments have shown that the study of metabolic activity
of brain areas is of crucial importance in the early diagnosis of degenerative
diseases or brain tumors. The monitoring and evaluation of the metabolic
processes of the body through the precious instrument of PET have added a
new dimension to the diagnosis and treatment of diseases, while also allowing
proper care and follow-up more targeted and timely.
PET uses radiopharmaceuticals that contain positron emitting radioiso-
topes, unlike other diagnostic technique imaging that uses radiopharmaceu-
ticals that directly emit gamma-rays. This emission occurs when a positron18 3.1 Positron Emission Tomography technique
emerge from the decay of nuclei of radioactive isotopes which are created
in cyclotrons speci￿cally dedicated to the synthesis of radiopharmaceuticals.
Positrons are subatomic particles that have all the features of electrons (ie,
mass, size, size of o￿ce), except the polarity of charge. When the electrons
collides with their corresponding positrons, electrons and positrons are de-
stroyed and their mass is transformed into a pair of high-energy gamma rays
that run away from the collision point towards opposite directions.
It’s on the basis of this principle that positrons emitted from radiophar-
maceuticals during PET scanning procedures are transformed into gamma
rays, that are then detected by a gamma camera or a PET scanner and
prospectively reconstructed into images.
The procedure of a PET exam starts with the intravenously injection
of the radiopharmaceuticals into a patient’s bloodstream. The tracer is dis-
tributed throughout the patient’s body and accumulates in the organ or body
system being examined where positrons are emitted and travel in the sur-
rounding tissue dispersing kinetic energy until they encounter and collide
with one of many nearby electrons. During the collision, the two particles
combine and destroy each other in a process that physicists refer to as anni-
hilation.
The annihilation of two particles produces a burst of energy that leads to
the generation of two 511-keV gamma rays (according to Einstein’s famous
equation: E = mc2), which radiate in opposite directions from each other,
thus forming a line of coincidence (Figure 3.1) . The coincidence line is the
indicator that annihilation has occurred somewhere along its trajectory and
it serves as a vital component in the detection scheme by which PET images
are created.
Figure 3.1: After annihilation (A), the two gamma rays are detected by the de-
tectors in the scanner that encircles the patient(B). PET scanner sorts
all the coincidences in a sinogram (C) and links to a computer that
reconstructs coincidence events to produce two- or three-dimensional
images (D).3.2 PET tracers 19
The two gamma rays, speeding away in opposite directions (180 degrees
apart) from each other, are detected on opposite sides of the patient’s body
by a PET scanner or a gamma camera that surrounds the patient as he or
she moves slowly through the scanner. The detection of this coincidence is
possible because the detectors (thousands of them) are arranged in a ring
con￿guration around the interior of the scanner (Figure 3.1), with each
detector having an associate partner detector on the opposite side of the
ring. In some instances, each detector consists of a scintillating crystal and a
photomultiplier tube but more recent and common con￿guration, the block
detector, consists of a rectangular bundle of crystals optically coupled to
several photomultipliers. When a gamma ray is sensed by a detector, the
gamma ray activates the scintillation crystal, which converts it into a burst
of light photons. The light photons are detected and ampli￿ed by a photo-
multiplier, and that event is registered by the electronics of the scanner.
The scanner electronics record the electronic signals and determine which
ones are coincident. The coincidence is determined considering a time frame
(coincidence window), based on which if two coincident gamma rays are
detected on opposite sides of the patient’s body within nanoseconds of each
other, the computer pairs and records them into coincident events, forming
a coincidence line.
The PET scanner collects all coincident events (usually about 500,000
events) and sorts them in the form of lines into a sinogram, which stores in-
formation in a way that is favorable for image reconstruction. The sinogram
is then reconstructed with corrections by a computer linked to the scanner
(Figure 3.1) to produce a two-dimensional image, that portray the activity
of the radiopharmaceutical in the patient’s . All commercially available PET
scanners simultaneously acquire data for three-dimensional images, either by
imaging the entire volume as a unit or by stacking adjacent two-dimensional
slices. Before the advent of the PET scanner, the study of physiologic phe-
nomena was not possible.
3.2 PET tracers
PET imaging process is based on the use of radiopharmaceuticals [19]. Most
radiopharmaceuticals contain two components: a carrier molecule that con-
tains a natural substrate, such as glucose, and a positron-emitting radioiso-
tope that labels the carrier molecule. Bound to each other, the carrier
molecule and the positron-emitting radioisotope make it possible for the
PET scanner to detect, record, and image the results of the collision and
interaction of emitted positrons with electrons inside the body in the form of
gamma radiation detected outside the body. It is important to point out that
the radioisotopes used in PET radiopharmaceuticals mimic substances, such
as sugars, water, proteins, and oxygen-substances that occur naturally in the
human body, and it is for this reason the radioisotopes can be used to label
natural substrates without altering the substrates’ biological and chemical
properties.
Most of the radioisotopes used in PET radiopharmaceuticals are man-
ufactured in a cyclotron. The cyclotron is a machine that accelerates pro-
tons by moving them along a circular orbit inside a chamber controlled by203.3 11C-MP4B : a radioligand for BuChE activity investigation
powerful electromagnetic ￿elds until the protons’ speed is near the speed of
light and smashes them into the nuclei of stable or nonradioactive elements
(e.g., ￿uorine, nitrogen, oxygen, and carbon), transforming the nonradioac-
tive elements into positron-emitting radioactive isotopes. The excess protons
acquired by the newly created radioisotopes during the particle acceleration
process that takes place in the cyclotron, cause the radioisotopes to be unsta-
ble, such that they decay by positron emission, in keeping with their innate
propensity to revert back to their stable state. Because they instinctively
try to return to their original stable state, PET radioisotopes have short
half-lives. While it is true that these short half-lives complicate the PET
procedure because of the time constraints they impose,the manufacture of
these radioisotopes and their transformation into PET radiopharmaceuticals
must take place inside or close to the PET imaging site where they are to be
used, this feature contributes to the low-risk pro￿les of PET radiopharmaceu-
ticals. Together the short half-lives of PET radiopharmaceuticals along with
their low levels of radiation make them ideal choices in terms of safe levels of
radiation for the patient.PET radiopharmaceuticals are usually synthesized
a single dose at a time and administered to the patient within minutes after
their synthesis.
Based on the body function that they measure, PET radioisotopes can
be divided into three categories. The ￿rst category includes radioisotopes,
such as Fluorine-18, that are used to measure such general metabolic data as
glucose uptake and protein synthesis. First category radioisotopes leave the
bloodstream and enter cells. Quite contrarily, the second category of radioiso-
topes, which includes Oxygen-15, remain in the bloodstream throughout the
study duration, making them appropriate candidates for measuring blood
￿ow. The third category, that we will deepen in the next section, is the
one of radioisotopes, such as Carbon-11, that quantify and delineate cellular
receptors.
3.3 11C-MP4B : a radioligand for BuChE activity
investigation
Because of their diagnostic potential and therapeutic values, investigators
have synthesized various radiolabeled acetylcholine and butyrylcholine analogs
as positron emission tomography (PET) tracers. These tracers are used to
quantify levels of ChE in human’s brains, to detect its activity and to verify
the e￿ciency of cholinesterase inhibitors. As said in the previous chapter,
more than AChE, BuChE may be an appropriate receptor to investigate
and diagnose Alzheimer’s Disease at an early stage of its onset because of
both a quantitative and a qualitative reason. First of all, researchers and
post-mortem studies demonstrated that the disfunctions of the cholinergic
system associated with AD are reduced levels of AChE but, for what con-
cern BuChE, its levels increase as much as 90% [6] [5]. In addition,to divert
the attention towards this new tracer, there are also technical and quali-
tative considerations, which deal with the fact that, at present, there are
no kinetic model globally suitable for quanti￿cation of AChE activity using
acetylcholine radiolabeled analogs.
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them, 1-11C-methyl-4-piperidinyl acetate (11C-MP4A) and 1-11C-methyl-4-
piperidinyl propionate (11C-MP4P) have already been used in the clinic as
PET tracers for in vivo assessment of AChE activity associated with AD [3]
[9]. Both are classi￿ed as irreversible radiotracers. These lipophilic acetyl-
choline analogs enter the brain by di￿usion and are hydrolyzed by AChE to
a common hydrophilic metabolite, which is trapped in the brain according to
the distribution of AChE activity. The standard method to estimate regional
hydrolysis rate of [11C]MP4A by AChE (k3; an index of AChE activity) is to
￿t the regional time-activity curve (TAC) obtained by PET to the theoretical
function derived from the kinetic model and the arterial input function using
nonlinear least squares (NLS) optimization [7]. In NLS analysis, however, the
procedure involves measurement of the arterial input function that is invasive
to patients and requires considerable technical expertise, which may restrict
widespread use of this method in daily clinical practice. In consequence of
this, several alternative methods have been proposed.
A ￿rst alternative analysis method without the use of an arterial input
function is the shape analysis, that has been proposed for estimation of re-
gional cerebral k3 of [11C]-PMP (Koeppe et al., 1999) [20] and [11C]-MP4A
(Tanaka et al., 2001) [21]. Shape analysis demonstrated to be very sensi-
tive to bias e￿ect of scan duration and showed larger coe￿cient of variation
(CV) of k3 estimates as compared with NLS analysis, particularly in regions
with high AChE activity. In the case of [11C]-MP4A, moreover, shape anal-
ysis allowed quantitative measurement of AChE activity only in neocortical
regions.
Nagatsuka et al. (2001) proposed, then, the Multi-linear Reference Tis-
sue Model for [11C]-MP4A (RLS), that is a method that uses a reference
with very high AChE activity, in contrast to reference methods for receptor
tracers which use a reference devoid of speci￿c binding [22]. Findings in dif-
ferent publications indicate that cerebellum yields more stable results than
striatum, most likely due to the higher impact of motion on the signal from
the small striatum than the large cerebellum. The sensitivity of RLS analysis
for detecting cortical regions with abnormally low k3 in patients with AD is
less than NLS analysis, but it is greater than shape analysis. Computer sim-
ulation studies showed that RLS analysis provides a precise index of AChE
in brain regions with low (for example, cortex) and moderate AChE activity
(hippocampus and thalamus). Despite the performance of this new method
are, in conditions of non advanced brain atrophy, much better than the ones
of the shape analysis, RLS for [(11)C]-MP4A is not suitable for quanti￿cation
in regions with high AChE activity.
1-11C-Methyl-4-piperidinyl n-butyrate , [(11)C]-MP4B, is a new ra-
diopharmaceutical for in vivo assessment of butyrylcholinesterase (BuChE)
activity using PET. It is the speci￿c substrate for BuChE and is inert for
AChE. The blood-brain barrier is impermeable to the hydrolyzed tracer 11C-
MP4B-OH; thus, the tracer accumulates in the tissue in a rate determined
by the local BuChE activity. Only a fraction of the injected tracer passes
the blood-brain barrier, leaving most of the radioactivity in the lower parts
of the body.
Investigators from several groups analyzed radiation dosimetry, biodis-
tribution and blood metabolism of 11C-MP4B to understand whether it can223.3 11C-MP4B : a radioligand for BuChE activity investigation
be considered as a viable candidate for the estimation of cerebral cholinergic
activity , in particular for patients su￿ering from AD [6].
Figure 3.2: Whole-body PET images of 22-y-old man, showing distribu-
tion of intravenously administered 11C-MP4B. Accumulation of
tracer is clearly visible in urinary bladder, renal pelvis, stom-
ach, liver, vertebral column, and salivary glands (arrows).
(http://jnm.snmjournals.org/content/45/12/2032.￿gures-only)
In a study of Roivainen et al. (2004) they analyzed the distribution and
kinetics of 11C-MP4B uptake in order to clarifying the metabolic fate and
the whole-body distribution of the tracer [23]. They investigated the time-
activity-course of radioactivity associated with 11C-MP4B and the analysis
showed that the level of unmetabolized radioligand decreases rapidly at 15
min after injection.
In their studies there were large individual variation in the rate of plasma
of 11C-MP4B hydrolysis but no signi￿cant di￿erences in degradation of 11C-
MP4B between male and female patients or between healthy controls and sick
patients. For what concerns the whole-body distribution, they found the
highest activity in, in order, urinary bladder, renal pelvis, stomach, salivary
glands, liver, kidneys, spleen, vertebral column, and brain (Figure 3.2). In
patients with AD, 11C-MP4B activity in the brain was highest in cerebellum,
followed by striatum, pons, and thalamus. Lower 11C-MP4B activity was
seen in cortical areas (Figure 3.3).
Eventually, biodistribution of 11C-MP4B in the brains of patients with
AD appears to be in accordance with the distribution of BuChE seen in
postmortem studies of human brain, except for the observed higher activity
in striatum than in cortex.
In a study of Virta et al. (2008) they analyzed and estimated the radiation-
absorbed doses of the 11C-MP4B in humans according to the guidelines of the
International Commission on Radiological Protection [24]. They compared
two di￿erent data acquisition protocols, dynamic organ-speci￿c evaluation
(DOSE) and whole-body scanning, both methods widely used for evaluation
of radiation burden of 11C-labeled PET tracers. Their results showed that
the organs with the highest radiation-absorbed were the liver and the urinary3.3 11C-MP4B : a radioligand for BuChE activity investigation23
Figure 3.3: (A) PET images showing radioactivity distribution in brain of
AD patient (70-y-old man) after 731-MBq intravenous injection of
11C-MP4B. Images are summated from 20 to 40 min after injec-
tion and color coded according to amount of radioactivity, from
dark blue (lowest) to hot red (highest). (B) Time-radioactivity
curves for cerebellum, striatum, cortex and corresponding total
and metabolite-corrected radioactivity curves of arterial plasma.
(http://jnm.snmjournals.org/content/45/12/2032.￿gures-only)
bladder,followed by kidneys (renal cortex), upper large intestine, trabecular
bone, salivary glands, and heart wall. More than 50% of the injected dose
was excreted via the urinary pathway with a quite rapid clearance: 30% of
the radioactivity excreted within 60 min after injection. Both DOSE method
and simulated whole-body imaging approach gave same results. They con-
cluded that 11C-MP4B causes less radiation burden than other 11C-labeled
PET tracers and there were non intolerably absorbed doses on critical organs
and this would allow multiple PET examinations during the follow-up of the
disease for the same subject.
Next step is now the development of a kinetic model to quantify the
cerebral cholinergic activity of BuChE with [11C]-MP4B through positron
emission tomography images.243.3 11C-MP4B : a radioligand for BuChE activity investigationChapter 4
Data sets and Methods
4.1 Data sets
In a typical PET study, PET data are sequentially obtained after the radioac-
tive tracer is introduced (usually administrated intravenously) over time. By
applying proper corrections for attenuation, dead-time of detector, physical
decay of radioactivity and scattered photons, PET data represent the tracer
concentration (in our case kBq/ml) at a certain time for the concerned sub-
ject.
Data sets were made available by a Finnish National Research Institute,
the Turku PET Centre.
4.1.1 Subjects
A group of 8 subjects, 6 of them patients a￿ected from Alzheimer’s Disease,
2 of them normal control subjects, participated at the study. Of the 6 pa-
tients with AD, 2 of them were under medical treatment with Rivastigmine
and we will refer to them as rivas01 and rivas07, 2 of them were under med-
ication with Donepezil and we will reference them with the name donep02
and donep04 and ￿nally the last 2 were not undergoing any treatment and
their reference will be nomed04 and nomed08. The two controls’ name will
be contr03 and contr05.
4.1.2 Plasma data
For each subjects arterial blood samples were available, both the activity
counts from entire blood (data with su￿x ap_comb.kbq ) and the activ-
ity counts from blood corrected for brain/collection site delay for tracer
metabolism, that means that only counts from pure tracer are going to be
taken in (data with su￿x ap_comp_pure_sinewf.delay.kbq ). All the blood
samples were automatically collected through the radial artery of the pa-
tients according to a sampling protocol which envisaged a higher frequency
at the beginning of the exam, when the tracer kinetic was faster, followed by
a gradually decreasing frequency as the exam reached its end: 115 intervals
of 5 seconds, 9/10 intervals of nearly 5 minutes. Each arterial sampling has
a duration of about 50 minutes (Figure 4.1, Figure 4.2 ). All data are
expressed in kBq/ml.26 4.1 Data sets
Figure 4.1: Activity counts of patient contr03 from both the entire blood and the
blood corrected for brain/collection site delay and tracer metabolism
Figure 4.2: Activity counts of patient donep02 from both the entire blood and the
blood corrected for brain/collection site delay tracer metabolism4.1 Data sets 27
4.1.3 PET images
PET images of [11C]-MP4B of the 8 subjects were available. All of them
were performed with a GE Advance PET scanner (General Electric Medical
Systems, Milwaukee, WI). Images were corrected for movement and both
normalized to MNI space and left on their native space (Figure 4.3). At the
start of the scan 11C-MP4B was injected in an antecubital vein as a constant
bolus during 80 s and images were acquired in times gradually increasing.
Radioactivity was measured in a consecutive series of 22 frames: 1x30 s, 4x15
s, 5x30 s, 2x60 s, 2x120 s,6x300 s, 2x600 s) with a total scan duration of 60
min.
Figure 4.3: PET images of,above, slice 20 and time 15 of subject contr03, below,
slice 16 time 20 of subject contr03. Images on the left are in their
native space, images on the right are normalized to the MNI space.28 4.1 Data setsChapter 5
Methods and Data Processing
5.1 Methods
Before describing the real work that has been done from the data at our
disposal, we will discuss very brie￿y the methods that were used. First, we
will describe the structures of Compartmental Models, their importance in
the study of brain images, their development from data and their solution.
After that we will brie￿y describe the types of quanti￿cation methods of PET
images, based on Region of Interest or on Voxel, relating in particular to the
method of the Basis Functions for non linear models solution.
5.1.1 Compartmental models
When trying to rationally explain the experimental data of a given biological
system arises the need to divide the system into building blocks of the system
itself, if they meet certain requirements, these compartments are enables not
only to visualize the distribution of PET radiotracer, but also to quantify
several biomedical functions. Compartmental model is the basic idea to
analyze dynamic PET data [25].
A compartment, in order to be considered as such, must comply some
requirements: its constituents must blend quickly, mixing must be uniform
and constituents present in its volume must all have the same probability of
moving into other compartments or outside. The requirement of homogene-
ity and identical behavior lead to an exponential law to express the kinetic
output and allow to propose mathematical models consist of systems of ￿rst
order linear di￿erential equations with constant coe￿cients. The compart-
mental model of a system is de￿ned by the various compartments and from
the connections that bind them together, the transfer coe￿cient, that ex-
presses the speed with which the process transfer from one compartment to
another.
There are various types of compartmental models for the kinetic study of
tracer. In principle, almost all the models are characterized by a compart-
mental group that describes the plasma kinetics and a set of compartments
which describes the behavior of the tracer once entered into the tissue. Re-
garding the tissue we can have up to three di￿erent compartments, with their
relative transfer constants: a compartment for the concentration of free tracer
in the tissue, a compartment for the concentration of tracer non-speci￿c lig-30 5.1 Methods
ated to receptors in the tissue and a compartment for the concentration of
tracer bound to speci￿c speci￿c receptors in the tissue. In particular this
latest one is of greater interest in the receptor study since it allows to locate
the neurologically speci￿c receptor sites for the radioligand. Regarding the
plasma we can have up to two compartments, in which the ￿rst describes the
concentration of free tracer in plasma, the second the concentration of tracer
bound to blood proteins. However, very often these compartments collapse
between them, because of lack of consistency or lack of su￿cient data to
estimate all the system variables, so we can have up to a unique blood com-
partment and a unique tissue compartment (Figure 5.1). What we can get
from the study of these models is the only plasma-tissue transfer constant
(K1), which expresses the rate at which the tracer crosses the blood-brain
barrier and di￿uses into the brain.
Figure 5.1: Mono compartmental model that describes the kinetics of a tracer. The
constants K1 and k2 are the transfer constants of the tracer between
the various compartments
The di￿erential equations that describe the concentration of tracer in
each of the compartments of a compartmental model have the structure of
the ones below, which are the equations of the model in Figure 5.1:
dCp(t)=dt = k2Ct(t)   K1Cp(t)
dCt(t)=dt = K1Cp(t)   (k2)Ct(t)
dCi(t)=dt is the change rate of the concentration of the tracer in the
compartment. The constants units are generally in min-1 and describe the
fraction of tracer that leaves the compartment in a time unit.
These equations can be solved with di￿erent methods, that we will discuss
later. Each method leads to the quanti￿cation of the constants of transfer of
the compartmental model or a composition of them. Such constants, in ad-
dition to having singularly their meaning, may give rise to other informative
parameters: there are two parameters of interest to measure the kinetics of
the tracer, the binding potential and the distribution volume, in the following
we’ll give their receptor-ligand kinetics de￿nitions.
Binding potential is a combined measure of the density of available
neuro-receptors and the a￿nity of a drug to that neuro-receptor.
Distribution volume of a radioligand is de￿ned as the ratio between
the radioligand concentration in tissue target region and radioligand concen-
tration in plasma at equilibrium.5.1 Methods 31
The binding potential can be calculated for those tracers whose kinetic
model is described by a 2- or 3-compartmental model, but not to those de-
scribed by a kinetic mono-compartmental model, which does not distinguish
between speci￿c binding and non-speci￿c. The distribution volume can be
achieved, however, for all tracers. In theory, the binding potential is prefer-
able to the distribution volume as we want to be sure that the di￿erences we
￿nd are due to di￿erences in the speci￿c binding of the tracer with the recep-
tors, not in non-speci￿c binding. Although the distribution volume in itself
has both speci￿c binding and non-speci￿c, its interest lies in the fact that it
is still proportional to the concentration of receptors available for binding.
It can be used when it is not possible to obtain accurate and reproducible
parametric images of binding potential, or when the kinetics of the tracer is
for most of the cases described by a mono-compartmental model.
A priori it is di￿cult to determine which is the most suitable model to
describe the kinetics of a tracer, so it is necessary to test di￿erent models,
validate them, and choose the one with best results and statistics.
5.1.2 Voxel based analysis: Basis Function Method (BFM)
The quanti￿cation of physiological information from dynamic studies is a
fundamental aspect of PET. Starting conditions are, in fact, a combination
of discrete spatial resolution of image acquisition combined with anatomical
regions of reduced dimensions to be studied and it is therefore of fundamental
importance that the estimates are accurate.
The quanti￿cation of the parameters can be done at the level of Region of
Interest or at voxel/pixel level. The pros and cons that could tip the choice to
a method rather than to another depend largely on what are the purposes of
the study and on the kinetics of the tracer. To solve the equations of models
such as those shown above, which are described by a non-linear kinetics, the
state of the art would use the Weighted Non-Linear Least Square (WNLLS).
This technique, although precise and e￿ective, however, requires a heavy
computational time, very often not compatible with the clinical requirements
and, as a consequence, not useful. In the following lines we will explain the
main features of the ROI- and voxel-based analysis, illustrating a particular
type of voxel-level quanti￿cation method: the Basis Function Method.
ROI level analysis consists on divide the scanned image into sub-regions
de￿ned according to criteria that can be of functional or morphologi-
cal type, make an average of the acquired signal in di￿erent voxels of
the region and then proceeding with WNLLS to calculate the unknown
kinetic parameters of the averaged signal. This technique allows to ob-
tain reliable estimates since the averaged signal has a good SNR and
does not require excessively long calculation times as the number of
iterations is greatly reduced. In so doing it is also possible to inves-
tigate speci￿c spatial regions, which may have relevant functional or
morphological meaning. The analysis in terms of ROI, however, has its
negative aspects, due primarily to the fact that it’s going to miss the
original spatial resolution of the image, secondly due to the problems
arising from the previous statistical analysis.32 5.1 Methods
Voxel level analysis solves the model for each element of the image pro-
ducing parametric maps having the same spatial resolution as the origi-
nal PET image. Due to the low SNR of the voxel kinetics and very high
number of voxels to be analyzed, that would require a high number of
iterations, nonlinear estimators cannot be used. Voxel level analysis
requires high computational time and, due to their sensitivity to initial
estimates, convergence, in general, is not guaranteed.
When the study requires a voxel level quanti￿cation, to overcome the
problem of nonlinear estimation, alternative methods can be used to combine
the advantages of the voxel-based analysis and, at the same time, lightening
the computational burden. One of this method is the Basis Function Method.
Basis Function Method (BFM)
Basis Function Method (Gunn et al., 1997) is a voxel-based method for quan-
ti￿cation of tracer’s kinetic parameters [26]. To explain how this method
works we will apply it to the simple plasma- tissue compartmental model of
Figure 5.1, that, once equations are solved, appears as follows:




The equation can be written also as:
CV OI(t) = K1Cp(t) 
 e k2t
and, more in general:
CV OI(t) = 1Cp(t) 
 e 2t
where 1 and 2 represent the generic parameters or composition of pa-
rameters to estimate. To solve the equation above it must be used a non-
linear method, but if we renounce estimating k2, and we assign it a deter-
ministic value, we can ￿rst solve the convolution operation and then go to
estimate, through a linear method, the value of k1. Formally, de￿ning j
the generic parameter for which we don’t give a statistical description, we
￿x a range (i.e. a grid) of M possible values of j and we pre-calculate for
each time frame (i=1,...nT, with nT the number of frames) a set of M basis
function (Bj) for the nonlinear term involving Cp(t) as:
Bj(ti) = Cp(ti) 
 e jti j = 1;:::;M
Once the (Bj) are solved we can use the Weighted Linear Least Square
to evaluate the remaining kinetic parameters (1 in the case above), solving
the problem of calculation burden. The accuracy of the estimates will then
depend, in large part, from the creation of the grid parameters, the real crux
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5.2 Data Fitting
The procedure of quanti￿cation of PET images requires a known input sig-
nal that provides information on the concentration of tracer and metabolic
residues of the tracer in the blood. It may happen that, when the samples
are collected by an automatic machine, the data are too noisy to be used
directly and they need to be ￿tted with an appropriate system. This is also
useful for estimating the measurement error associated with the samples. For
this purpose we used the software SAAM II.
5.2.1 SAAM II - Numerical
Simulation, Analysis, and Modeling Software II (SAAM II) is a software
package available for tracer and pharmacokinetic analysis. The SAAM II
system, a totally reengineered software system based on Berman’s SAAM
[27], is a powerful research tool to aid in the design of experiments and
the analysis of data [28]. SAAM II deals easily with compartmental and
numerical models, helping researchers create models, design and simulate
experiments, and analyze data quickly, easily and accurately.
(a) Equation Builder tool . (b) Parameters tool.
Figure 5.2: SAAM II Numerical Module tools
In the numerical module of SAAM II, user can enter algebraic equations
manually or select them from a set of prede￿ned templates as polynomi-
als, exponential sums, sums of Gaussian, Michaelis Menten equations and
Scatchard analysis. The software solves the equations and ￿ts them to the
data. The Equation Builder window (Figure 5.2 (a)) is used to select one of
a prede￿ned set of equations for the Numerical Module and if Sum of Expo-
nentials is chosen, user must also select the type of experimental exogenous
input.
As for the weights to be assigned to the data, where d(ti) (i = 1;:::;N)
are the experiment data, SAAM II allows to assign the standard deviation
of measurement error using one of the options in Table 5.1.
In addition, if a series of data have not to be considered, this assumption
is speci￿ed in SAAM II typing, after the data, the sequence: ( ).34 5.2 Data Fitting
SAAM II formulations Standard Deviation
(SD ) i = 
(FSD ) i = d(ti)
(POIS ) i =
p
d(ti)
(GEN a b c) i =
p
a + bd(ti)c
Table 5.1: Formulation of the standard deviations with SAAM II
The statistical information, available following a successful ￿t of the
model to the set of data, are: best estimates for both the primary param-
eters and derived parameters (functions of the primary parameters), their
estimated standard deviation, their fractional standard deviations and 95%
con￿dence limits. The correlation coe￿cients were also provided. Additional
options included the covariance matrix and information on the objective
function.
5.2.2 Arterial and Metabolic Input Function
Starting from only visual inspection of the data it was possible to notice
some irregularities in the descent curve of the arterial signal, both for the
data relating to whole blood, and for those corrected for metabolic component
(Figure 5.3).
Figure 5.3: Activity counts of patients nomed04 and donep02. In the ￿rst one the
"false" peak is visible, in the second not.
The nature of the irregularity detected was refered to be a noisy artifact.
This "false" peak irregularity was more visible in some subjects than in
others, with no distinction between sick patients and controls, in particular
it was more pronounced in rivas and nomed groups than in others. We chose
to delete the data related to these "false" peaks to allow the software to
achieve a better optimization, an example on Figure 5.4 .
Before solving, we set the initial values of the parameters specifying if
they’re adjustable or ￿xed and giving the bound within the quanti￿cation
process can range, in particular to avoid that the optimization did not cross
the frontier of the physiologically acceptable values (Figure 5.2 (b)).5.2 Data Fitting 35
Figure 5.4: Activity counts of patient nomed04 with and without "false" peak data
Data weights have been set as SD =
p
di that corresponded at (POIS
1) in SAAM II standards (Table 5.1).
For choosing the best descriptive model, within various attempts pro-
posed by the software, which were optimized on the available data and on
the basic structure that each times we provided, we considered various fac-
tors. First we looked at the trends, more or less polarized, of the weighted
residues, then the values, physiologically acceptable or not, of the hypothet-
ical identi￿ed parameters and eventually we tryed to always prefer simple
models.
(a) y(t) for rivas07 . (b) Weighted residuals.
(c) y(t) for rivas07 without data. (d) Weighted residuals without data.
Figure 5.5: Models attempts for rivas07 with and without "false" peak data36 5.2 Data Fitting
Models that showed an inferior polarization of residues were privileged, in
particular we compared the performance of models built from the complete
data set with models built on the data set without those data related to the
"false" peak. In the case of the patient rivas07, for blood data corrected
for brain/collection site delay and for tracer metabolism, it’s possible to see
(Figure 5.5) how, once the peak of the false data had been deleted, the
program was able to identify a function that ￿t better the data and, in
addition to visual inspection, this is also con￿rmed by the sharp decrease of
polarization of the weighted residues.
The choice was more sensitive to those patients in whom the elimination
of the peak would result in a substantial loss of data. In some cases, in
fact, the elimination of a big portion of the data set has changed much of the
result of the ￿t, leading to have more exponential components, low parameter
values and therefore not very signi￿cant. In such cases, even the weighted
residuals seemed to be less polarized, we prefered the model ￿tted on the
original data set (Figure 5.6).
(a) Model with original data set for nomed04 .
(b) Model with data set without noisy data for nomed04 .
Figure 5.6: Comparison between two plausible models for nomed04, in (a) the
model optimized on the original data set, composed of two exponen-
tials, and related weighted residues , in (b) the model optimized on the
lighter data set, composed of three exponentials where a3 is very low,
and related weighted residuals5.2 Data Fitting 37
Starting from these considerations, the models chosen to ￿t the arterial
data from whole blood and from blood corrected for brain/collection site
delay and for tracer metabolism for each patient are shown in Table 5.2 and
Table 5.4.
Subject Fitting optimization model for entire blood data
contr03 ya(t) = 228:66e 2:157t + 73:442e 0:42t + 8:798e 0:069t + 5:175
contr05 ya(t) = 470:663e 0:994t + 18:426e 0:092t + 7:594
donep02 ya(t) = 171:885e 0:608t + 14:536e 0:056t + 5:693
donep04 ya(t) = 246:162e 0:938t + 15:064e 0:126t + 7:492e 0:006t
nomed04 ya(t) = 1737:285e 1:983t + 28:985e 0:127t + 7:131
nomed08 ya(t) = 1085:433e 1:858t) + 19:671e 0:167t + 9:815e 0:002t
rivas01 ya(t) = 1266:857e 1:869t + 22:562e 0:169t + 9:475e 0:005t
rivas07 ya(t) = 463:317e 1:436t + 14:078e 0:115t + 6:456
Table 5.2: Fitting model for entire blood data for each subject
Subject A2 A3 A4 a1 a2 a3 A1-derived
contr03
value 73.442 8.798 5.175 2.157 0.420 0.069 228.66
CV 18% 51% 20% 76% 20% 76% 200%
contr05
value 18.426 7.594 - 0.994 0.092 - 470.663
CV 6% 5% - 2% 12% - 2%
donep02
value 14.536 5.693 - 0.608 0.056 - 171.885
CV 7% 22% - 3% 33% - 1%
donep04
value 15.064 7.492 - 0.937 0.126 0.006 246.162
CV 16% 48% - 4% 44% 213% 3%
nomed04
value 28.985 7.131 - 1.983 0.127 - 1737.283
CV 7% 10% - 6% 12% - 17%
nomed08
value 19.671 9.815 - 1.858 0.167 0.002 1085.433
CV 14% 30% - 7% 36% 345% 18%
rivas01
value 22.562 9.475 - 1.869 0.169 0.005 1266.857
CV 10% 27% - 5% 25% 130% 11%
rivas07
value 14.078 6.456 - 1.436 0.115 - 463.317
CV 5% 5% - 2% *Fixed* - 4%
Table 5.3: Parameters statistics for entire blood AIF
Parameters statistic description is shown in Table 5.3 and Table 5.5.
The A1-derived parameters are obtained from the setting of initial conditions
of the equations: tmax, time of maximum value from which we have data38 5.2 Data Fitting
samples, y(tmax), sample value at tmax. Once the most suitable model have
been found, we started the ￿tting process from time t=0 for each function.
Subject Fitting optimization model for corrected blood data
contr03 ya(t) = 45:126e 1:954t + 8:571e 0:551t + 0:575e 0:102t + 0:037
contr05 ya(t) = 105:99e 1:026t + 2:688e 0:117t + 0:140
donep02 ya(t) = 59:307e 0:8t + 3:108e 0:106t + 0:221
donep04 ya(t) = 98:195e 1:136tt + 4:325e 0:224t + 0:639e 0:03t
nomed04 ya(t) = 444:006e 2t + 6:555e 0:185t + 0:301
nomed08 ya(t) = 288:882e 2:017t + 4:622e 0:274t + 0:717e 0:028t
rivas01 ya(t) = 463:965e 1:634t + 13:131e 0:189t + 2:349e 0:017t
rivas07 ya(t) = 153:376e 1:531574t + 3:65e 0:135t + 0:352
Table 5.4: Fitting model for blood data corrected for brain/collection site delay
and for tracer metabolism for each subject
Subject A2 A3 A4 a1 a2 a3 A1-derived
contr03
value 8.571 0.575 0.037 1.954 0.551 0.102 45.126
CV 22% 35% 35% 22% 13% 30% 46%
contr05
value 2.688 0.140 - 1.026 0.117 - 105.990
CV 11% 28% - 2% 14% - 2%
donep02
value 3.108 0.221 - 0.800 0.106 - 59.307
CV 8% 16% - 2% 11% - 1%
donep04
value 4.325 0.639 - 1.136 0.224 0.030 98.195
CV 17% 63% - 3% 26% 61% 3%
nomed04
value 6.555 0.301 - 2.000 0.185 - 444.006
CV 6% 15% - 4% 6% - 11%
nomed08
value 4.622 0.717 - 2.016 0.274 0.028 288.882
CV 14% 39% - 5% 20% 47% 14%
rivas01
value 2.349 - - 1.634 0.189 0.017 463.965
CV 54% - - 5% 22% 85% 9%
rivas07
value 3.650 0.352 - 1.532 0.135 - 153.376
CV 7% 12% - 2% 10% - 4%
Table 5.5: Parameters statistics for AIF corrected for brain/collection site delay
and for tracer metabolism
From these mathematical description of the data we evaluated the metabolic
component (Cmet) making a subtraction from entire blood ￿tted data and
the ￿tted data of blood corrected for brain/collection site delay and for tracer5.3 Modelling 39
metabolism. The purpose of this operation was to construct a function of the
only blood metabolic component that we used in the following as the second
input function requested in our kinetic model.
5.3 Modelling
To describe the dynamics of PET images we had to get from a complex
physiological system to a highly simpli￿ed compartmental model. The state
of art for [11C]-MP4B did not o￿er a compartmental model that could de￿ne
the kinetics of the tracer, so the following step was to develop a suitable
compartmental model. For this purpose it has been used the compartmental
module of software SAAM II. In the following there are some short technical
features of the software, useful to have a complete view of how it works.
5.3.1 SAAM II - Compartmental
In the compartmental module, the user can choose from a set of drag and
drop model-building icons representing compartments, transfers, and delays
to build a visual representation of a system on a drawing canvas. For each
icon, attributes can be de￿ned using dialogue boxes such as for the numerical
module. Once the structure of the model is built, to simulate the behavior
user must create an experiment. Even in this case, by exploiting the various
toolbox the user inserts the various speci￿cations related to the experiment,
such as the functional form for the input function. Once the user speci￿es
the structure and the inputs and outputs, SAAM II automatically creates
the corresponding system of ordinary di￿erential equations and simulates
solutions given speci￿c parameter values and input information.
There are two basic numerical computations performed by SAAM II,
solving systems of ordinary (linear or nonlinear) di￿erential equations and
optimization. Parameters within the model that are not speci￿ed by an
equation can be estimated by the optimization procedure.
SAAM II provides a choice of three integration methods: the Rosenbrock
(the default one), the Runge-Kutta and the Pade integrator. Each integrator
has di￿erent strengths and weaknesses, which will not in￿uence the correct-
ness of the results but may dramatically in￿uence the running time of a solve
or ￿t operation.
The optimizer is a modi￿cation of the Gauss-Newton method that han-
dles the case of multiple data sets, where data sets can di￿er numerically
by several orders of magnitude. The speci￿c formulation of the objective
function allows adjustment of the parameters not only to achieve an optimal
￿t to the data but also (in the case of model, relative weighting) to optimize
the variance of the data with respect to the available information. Asymp-
totic parameter precisions are given by SAAM II for all available weighting
schemes (data- or model-based and absolute or relative).
5.3.2 Compartmental Models for [11C]-MP4B
For the formulation of the model it is not possible to give general rules. The
proposed model will depend on a number of factors related to physiologi-40 5.3 Modelling
cal knowledge, pathological and pharmacological aspects, by analogy with
similar models etc.
To propose a model for [11C]-MP4B kinetics we started from the gen-
eral structure of a compartmental model for the kinetic study of tracers
and we considered the fact that the metabolic component associated to this
tracer was very signi￿cative and we took into account to include, in our de-
velopment, a portion of the model that may describe the behaviour of the
metabolic products.
Figure 5.7: Model proposed for [11C]-MP4A, Iyo et al (Lancet 349:1805-09, 1997)
We started from the model proposed for [11C]-MP4A (Figure 5.7), pub-
lished by Iyo et al. (Lancet 349:1805-09, 1997) and we proposed for [11C]-
MP4B two alternative suitable models with nearly the same structure: Model
A (Figure 5.8) and Model B (Figure 5.9).
Model A
The structure of the model provides, at plasma level, a compartment for the
tracer and a compartment for the metabolized product and, at tissue-level,
a compartment for the tracer and a compartment for the ligated metabolite.
None of the four compartmets distinguishes between free, or speci￿c ligated
or non speci￿c ligated elements. Plasma and tissue compartments of the
tracer are connected by constant transfer in both directions, those of the
metabolite from the only plasma-tissue transfer constant. The two tissue
and the two plasma compartments don’t exchange substances to each other.
The equations that describe the model are the follows:
dC3(t)=dt = k(3;1)C1(t)
dC4(t)=dt =  k(1;2)C4(t) + (k(2;1))C2(t)
where the compartment 3 and 4 are respectively the tissue-tracer compart-
ment (C3) and the tissue-metabolite compartment (C4), while compartment 1
and 2 are respectively the plasma-tracer compartment (Cp) and the plasma-
metabolite compartment (Cmet). The transfer costant k(3;1) indicates the
transfer rate of the tracer between plasma and tissue, the constants k(4;2)
has the same meaning but it refers to the metabolite and the k(2;4) indicates
the transfer rate of the metabolite return from tissue to plasma. From now
we will refer to compartment 1 as the Cp compartment, to compartment 2
as the Cmet compartment and the constant transfers k(3;1), k(4;2) and k(2;4)
will be refered to as K1, k1met and k2met.5.3 Modelling 41
Figure 5.8: Model A proposed for [11C]-MP4B
The acquired signal is:







where it was introduced the Cb component of whole blood and the parameter
VB that is a correction for the vascular volume presence.
The parameters that are going to be estimated are K1, k1met, k2met and
VB
Model B
The structure of the model is the same as the previous, the only di￿erence is
the adding of a transfer costant k2 that quantify the rate of transfer of the
[11C]-MP4B tracer from the tissue to the plasma.
The equations that describe the model are the follows:
dC3(t)=dt =  k(1;3)C3(t) + k(3;1)C1(t)
dC4(t)=dt =  k(1;2)C4(t) + (k(2;1))C2(t)
where the compartment 3 and 4 are respectively the tissue-tracer compart-
ment (C3) and the tissue-metabolite compartment (C4), while compartment 1
and 2 are respectively the plasma-tracer compartment (Cp) and the plasma-
metabolite compartment (Cmet). The transfer costant k(3;1) indicates the
transfer rate of the tracer between plasma and tissue and the k(1;3) indicates
the transfer rate of the tracer return from tissue to plasma. Transfer costants
k(4;2) and k(2;4) have the same meaning but they refer to the metabolite. From
now we will refer to compartment 1 as the Cp compartment, to compartment
2 as the Cmet compartment and the constant transfers k(3;1), k(1;3), k(4;2) and
k(2;4) will be refered to as K1, k2, k1met and k2met.
The acquired signal is:






Cmet(t)e k2met(t ))+VbCb42 5.4 Cluster Analysis
Figure 5.9: Model B proposed for [11C]-MP4B
where Cb and VB are, as the previous model, the component of whole blood
and the correction for the vascular volume presence.
The parameters that are going to be estimated are K1, k2, k1met, k2met
and VB.
5.4 Cluster Analysis
Cluster analysis, or clustering, is the task of grouping a set of objects in such
a way that objects in the same group (called cluster) are more similar (in
some sense or another) to each other than to those in other groups [29]. It is
a non-supervised classi￿cation method, that means that, a priori, you don’t
know the representative patterns of each class. In general, there are di￿erent
methods of Cluster Analysis:
Connectivity-based clustering is based on the core idea of objects being
more related to nearby objects than to objects farther away. Typi-
cally, it uses the simple Euclidean distance and assesses the degree of
closeness between clusters according to a rule of connection. It doesn’t
require the number of desired cluster as input, but require a termi-
nation condition, for example, a distance-threshold. It’s simple from
the implementation point of view but also the most computationally
burdensome and it can be applied in imaging area only if the number
of pixels is reasonable.
Centroid-based clustering is based on the idea of using, to represent clus-
ters, a central vector, which may not necessarily be a member of the
data set. This method is fast and easy, but the number of clusters must
be ￿xed a priori and because of the mean calculation it is sensible to
noise and outliers.
Distribution-based clustering is the most closely related to statistics and
it is based on distribution models. Clusters can be de￿ned as objects5.4 Cluster Analysis 43
belonging most likely to the same distribution. While the theoreti-
cal foundation of these methods is excellent, they su￿er from one key
problem known as over￿tting, unless constraints are put on the model
complexity.
Density-based clustering de￿ne clusters as areas of higher density than
the remainder of the data set. Objects in these sparse areas - that are
required to separate clusters - are usually considered to be noise and
border points.
Among various methods we used the central-based clustering. In the
next section we will describe this method more in detail and we will show
the results of its application to our data.
5.4.1 Centroid-based clustering
Compared to other types of clustering algorithms, centroid-based algorithms
are very e￿cient for clustering large databases and high-dimensional databases.
The optimization problem itself is known to be NP-hard, and thus the com-
mon approach is to search only for approximate solutions. A particularly well
known approximative method is Lloyd’s algorithm, often actually referred to
as "k-means algorithm" [30].
K-means clustering is a method of cluster analysis which aims to par-
tition n observations into k clusters. The main idea is to de￿ne k centroids,
one for each cluster. These centroids shoud be placed in a cunning way be-
cause of di￿erent location causes di￿erent result. So, the better choice is to
place them as much as possible far away from each other. The next step is to
take each point belonging to a given data set and associate it to the nearest
centroid. When no point is pending, the ￿rst step is completed and an early
groupage is done. At this point we need to re-calculate k new centroids as
barycenters of the clusters resulting from the previous step. After we have
these k new centroids, a new binding has to be done between the same data
set points and the nearest new centroid. A loop has been generated. As a
result of this loop we may notice that the k centroids change their location
step by step until no more changes are done. Finally, this algorithm aims at











i   cjk2 is a chosen distance measure between a data point x
(j)
i
and the cluster center cj.
The algorithm pseudo-code:
Inputs:
I={i1,...,1k } instances to be clustered ,
n number of clusters
Outputs:
C={c1,...,cn } cluster centroids ,
m: I ---> C cluster membership44 5.4 Cluster Analysis
Procedure of K-means:
Set C to initial value (e.g. random selection of I)




While m has changed
For each j in {1...n}
Recompute i_j as the centroid of{i|m(i)=j}
End %end for




End % end while
Return C
K-means is a simple algorithm that has been adapted to many problem
domains, by the way it has some problems:
1. the number of cluster must be speci￿ed before running
2. it can be sensitive to initial random choice of centroids
3. sometimes it doesn’ t ￿nd the absolute optimum but just a local one
4. it doesn’t make any use of class information
In addition to these disadvantages, a feature of the k-means is making
deterministic assignement type: each measure xi is assigned to one and only
one cluster assignement. A di￿erent clustering method, the Fuzzy-C-means
(FCM), is a "soft" alternative that, instead of making a deterministic deci-
sion, considers the possibility for a measure to bind with more than one
class.










the only di￿erence is the introduction of a vector pm
nk which expresses the
percentage of belonging of a given point to each of the clusters: the fuzzy
index. This vector is submitted to a "sti￿ness" exponent aimed at giving
more importance to the stronger connections (and conversely at minimizing
the weight of weaker ones).
The algorithm is nearly the same, the only di￿erence is that in the Fuzzy-
C-means, at every step, they must be recalculated not only the clusters’
centroids but also the probabilities. Beacuse of this, in terms of burden
FCM is a little bit heavier, but it can take advantages from class information
and it will never end on a local minimum.
We applied FCM and k-means to our datasets to get an automatic func-
tional partition of subjects brain areas.5.4 Cluster Analysis 45
5.4.2 PET images Cluster Analysis for automatic generation
of ROI
Cluster Analysis of the Time Activity Curve (TAC) provided the generation
of functional ROIs. For each TAC it was made a parametrization of the
curve features and then the Cluster Analysis was performed on the following
parameters.
Figure 5.10: Simpli￿ed version of a Time Activity Curve where the following pa-
rameters are highlighted: peak value, tail value, Area Under Curve.
AUC identi￿es the Area Under Curve of Time Activity Curves (Figure 5.10)







mWashout1 is a parameter description of the slope of the descent phase of













end46 5.4 Cluster Analysis
mWashout2 is a parameter description of the slope of the descent phase of














peak identi￿es the peak value of Time Activity Curves (Figure 5.10)
tail identi￿es the tail value of Time Activity Curves (Figure 5.10)
peak/tail identi￿es the ratio between the peak and the tail values of each
Time Activity Curve.
We moved, then, to cluster analysis by applying, in sequence, the fuzzy-
C-Means and the k-means algorithms.
Figure 5.11: Centroids’ trents of subject nomed04
It was possible to choose the parameters from which the clustering was
applied, in the case where the carrier parChoice was equal to 0 the program5.4 Cluster Analysis 47
performed the cluster analysis on PET TACs. Results of Clustering are
shown in Figure 5.12 and in Figure 5.11.
The ￿rst image displays some slices of the patient nomed04 that show
the partition of the scalp reaching up to a maximum of 12 clusters. The
trends of the centroids of each cluster (dashed line), each with his band of
variability (green band), are plotted in Figure 5.11.
Among the 12 clusters identi￿ed by the analysis, cortex, cerebellum, tha-
lamic, hypotalamic and caudate nucleus regions are always visible and more
or less partitioned into di￿erent clusters in each of the 8 subjects (Figure
5.12). .
Figure 5.12: Slices of subject nomed04 that shows the clusterization of the scalp48 5.4 Cluster AnalysisChapter 6
Results: Region of Interest
quanti￿cation method
Quanti￿cation at Region of Interest level was applied in order to have esti-
mates for unknown parameters K1, k1met, k2met and, only for Model B, k2.
The analysis was performed with SAAM II, whose features and functioning
were described in previous chapters.
The decision to perform a ￿rst quanti￿cation in terms of ROI had a dual
purpose: in order to draw early considerations on which of the two proposed
models could be the most appropriate to describe the kinetics of the tracer
and in order to get ￿rst estimates of parameters values that we could use as
prior in the later Bayesian quanti￿cation.
To get the estimates it was necessary to create an experiment, that means
entering requested data and specify the equations system that SAAM II
doesn’t already create itself.
Forcing Functions (FF) : the ￿tted function from arterial plasma tracer,
Cp and the ￿tted function obtained for the metabolite Cmet, have been
speci￿ed as FF for compartment 1 and 2 and their values inserted in
Data box tool.
Measure equation (s1) : the signal acquired s1 have been associated to
the speci￿c data it refers to (ROI1, ROI2, etc) and its equation was
made explicit in the SAAM II form:
s1 = (1   V b)  (q4 + q3) + V b  lin(Cb)
where s1 is the acquired signal, V b the vascular volume presence, q3
and q4 are the amount of substances in compartment 3 and 4 and Cb
the entire blood sampling.
ROI data : data obtained from previous cluster analysis, on which the
estimation was performed, were entered into a form compatible with
the mode of SAAM II. For each patient and for each ROI, the estimated
trends of the 12 centroids were inserted, the weighted were imposed as
SD =
p
d(ti), (SD 1 in SAAM II), where d(ti) are the centroids data
values. In that cases in which there were physiologically unacceptable
values, we chose to impose zero weight, which corresponds to writing
( ) in SAAM II.50 6.1 Model A
The quanti￿cation returned the parameters values and the relative sta-
tistical information: SD, CV, 95% con￿dence interval, Correlation and Co-
variance matrix, value of the Objective Function and of the Akaike (AIC)
and Schwarz (BIC) indexes.
6.1 Model A
Structure of Model A requires the parameters K1, k1met and k2met to be
estimated:







The Table 6.1 shows the parameters values and their related Coe￿cient of
Variation in the 12 ROIs for the 8 subjects.
In 18% of cases Vb cannot be considered valid, both because the software
does not lead to a successful result and is not enable to return a value and
a statistic description and because its estimated CV are higher than 100%.
For the whole group, Vb in Region of Interest 8 is never estimated.
k1 shows acceptable values in contr and donep subjects groups, but for
patients of rivas and nomed groups, the percentage of non estimated param-
eters riches more than 50% of values. In all subjects k1 cannot be estimated
in ROI 1.
Subject ROI 1 ROI 2 ROI 3 ROI 4 ROI 5 ROI 6 ROI 7 ROI 8 ROI 9 ROI 10 ROI 11 ROI 12
contr03
Vb 0.0127 0.0170 0.0243 0.0269 0.0407 0.0158 0.0126 - 0.0307 0.0467 0.0303 0.0230
CV Vb 647 % 20% 29% 47% 20 % 29% 81 % 25% 16% 21% 41%
k1 - 0.1169 0.0255 0.0907 0.1512 0.1871 0.7199 0.7357 0.2864 0.1327 0.2725 0.0953
CV k1 9% 3% 13% 6% 10% 2% 2% 6% 6% 3% 10%
k1met 0.1728 0.0304 0.3549 0.5407 0.1378 0.0408 0.3597 0.4958 0.0938 0.2595 0.2121 0.4052
CV k1met 93% 6% 2% 2% 5% 6% 3% 2% 5% 3% 2% 2%
k2met 0.6487 0.1175 0.2695 0.3335 0.2671 0.1022 0.3158 0.3645 0.1566 0.2802 0.2202 0.3009
CV k2met 79% 9% 3% 3% 7% 10% 4% 3% 8% 3% 3% 3%
contr05
Vb 0.0330 0.0197 0.0212 0.0163 0.0248 0.0175 0.0252 - 0.0026 0.0073 0.0056 0.0317
CV Vb 9% 16% 10% 14% 7% 12% 19% 241% 69% 91% 11%
k1 0.0397 0.1217 0.0403 0.1163 0.0325 0.0993 0.0231 0.0447 0.3855 0.3356 0.1096 0.0501
CV k1 - 3 % 4% 2% 4% 2% 23% 8% 1% 1% 3% 5%
k1met 0.1878 0.0817 0.3542 0.2443 0.2800 0.1791 0.0324 0.0212 0.2910 0.2331 0.0337 0.1000
CV k1met 1% 3% 1% 1% 1% 1% 8% 10% 2% 2% 20% 3%
k2met 0.1763 0.1544 0.1950 0.1730 0.1805 0.1640 0.1136 0.1451 0.2469 0.2251 0.2931 0.1860
CV k2met 2% 5% 1% 1% 1% 2% 13% 17% 4% 4% 26% 4%
donep02
Vb 0.0046 0.0070 - - 0.0141 0.0190 0.0147 0.0130 0.0096 0.0253 0.0038 0.0059
CV Vb 43% 93% 14% 23% 14 % - 22 % 12% 279% 60%
k1 0.0720 0.0332 0.1273 0.2678 0.0679 0.0262 0.0289 0.0271 0.0561 0.0351 0.0427 0.0830
CV k1 - 9% 5% 1% 2% 8% 4% 14 % 4% 4% 11% 2%
k1met 0.1971 0.3252 0.5105 0.3041 0.1170 0.2353 0.0306 0.0325 0.0393 0.1118 0.4339 0.2881
CV k1met 1% 2% 3% 1% 1% 2% 4% 11% 4% 2% 3% 1%
k2met 0.1710 0.2268 0.2582 0.2365 0.1632 0.2234 0.1378 0.1420 0.1251 0.2065 0.2477 0.1986
CV k2met 1% 3% 4% 2% 2% 2% 5% 16% 6% 3% 4% 2%
donep04
Vb 0.0148 0.0323 0.0054 0.0078 0.0108 0.0128 0.0187 0.0102 0.0073 0.0247 0.0126 0.0012
CV Vb 14% 13% 73% 32% 12% 19 % 13 % - 27% 17% 31% 216%
k1 0.0558 0.0337 0.1510 0.1733 0.0907 0.0685 0.0568 0.0906 0.0324 0.0189 0.0104 -
CV k1 - 7 % 2 % 1% 1% 2 % 3% 1% 7% 14% 19%
k1met 0.0886 0.1679 0.4040 0.2848 0.2297 0.3403 0.2417 0.1418 0.0354 0.0866 0.0425 0.0056
CV k1met 2% 2% 1% 1% 1% 1% 1% 1% 4% 4% 9% 13%
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Subject ROI 1 ROI 2 ROI 3 ROI 4 ROI 5 ROI 6 ROI 7 ROI 8 ROI 9 ROI 10 ROI 11 ROI 12
k2met 0.1534 0.1917 0.2299 0.2053 0.1812 0.2203 0.2009 0.1608 0.1207 0.1713 0.2051 0.0425
CV k2met 3% 3% 2% 1% 1% 1% 1% 1% 7% 6% 11% 17%
nomed04
Vb 0.0403 0.0494 0.0363 0.0285 0.0203 0.0447 - 0.0290 0.0357 0.0359 0.0418 0.0387
CV Vb 15% 11 % 29% 41 % 20 % 14 % - 19 % 15% 13% 17%
k1 0.0520 0.0096 0.1871 0.1906 0.0451 0.0229 0.0278 0.0281 0.0622 0.0137 0.0100 0.0603
CV k1 - 21% 3% 3 % 7 % 10% 16% 13% 5 % 15% 21% 6%
k1met 0.1533 0.2990 0.3795 0.4883 0.0550 0.1469 0.0291 0.0490 0.3545 0.5276 0.4097 0.2460
CV k1met 3% 2% 3% 3% 5% 4% 9% 14% 2% 1% 1% 2%
k2met 0.1920 0.2627 0.2608 0.2921 0.1514 0.2426 0.1227 0.2110 0.2317 0.2879 0.2665 0.2032
CV k2met 4% 2% 4% 4% 8% 5% 14% 18% 3% 2% 2% 3%
nomed08
Vb 0.0395 0.0120 0.0285 0.0574 0.0559 0.0450 0.0536 0.0583 0.0622 0.0700 0.0836 0.0847
CV Vb 18% 21 % 16 % 28% 39 % 12 % 66% - 59 % 7% 12% 13%
k1 0.0036 0.0247 0.0558 - - 0.0729 - 0.0128 - 0.0011 0.2099 0.2664
CV k1 - 18 % 11 % 11 % 44% 457% 5% 4%
k1met 0.0679 0.0378 0.0700 0.1699 0.3028 0.1218 0.4256 0.2332 0.5133 0.3344 0.3588 0.4342
CV k1met 6% 4% 4% 8% 8% 3% 9% 1% 8% 1% 2% 2%
k2met 0.1481 0.1308 0.1510 0.2316 0.2816 0.1490 0.3067 0.1699 0.3069 0.1895 0.2046 0.2234
CV k2met 10% 7% 7% 8% 8% 5% 10% 2% 9% 2% 4% 4%
rivas01
Vb 0.0252 0.0167 0.0309 0.0252 0.0135 0.0136 0.0369 0.0193 0.0273 0.0170 0.0224 0.0267
CV Vb 26% 26% 213% 63 % 490 % 226 % 335% - 342% 212% 18% 91%
k1 0.0011 0.0020 - - - - - - - - 0.0023 -
CV k1 - 72% 79%
k1met 0.1098 0.1000 0.6926 0.3731 1.3632 1.0550 1.2349 0.9111 0.9563 0.5851 0.1533 0.3886
CV k1met 8% 5% 30% 8% 13% 7% 34% 20% 31% 12% 3% 16%
k2met 0.1751 0.1617 0.4091 0.2222 0.3681 0.2916 0.4571 0.3352 0.4259 0.2475 0.1492 0.3380
CV k2met 12% 8% 31% 8% 15% 7% 38% 22% 34% 13% 5% 16%
rivas07
Vb 0.0280 0.0369 0.0244 0.0277 0.0245 0.0134 0.0352 0.0360 0.0261 0.0212 0.0186 0.0357
CV Vb 17 % 40% 25 % 85% 45% 18 % 20% - 51 % 157% 18% 21%
k1 0.0060 - - - - 0.0076 0.0509 0.0386 - - 0.0067 -
CV k1 - 32 % 10 % 15% 59%
k1met 0.1237 0.2338 0.2186 0.3470 0.1020 0.0435 0.3827 0.4973 0.3242 0.4645 0.0746 0.1407
CV k1met 2% 6% 2% 7% 11% 3% 2% 2% 3% 8% 3% 4%
k2met 0.1067 0.1902 0.1310 0.2088 0.2305 0.1146 0.1664 0.1887 0.1608 0.2315 0.1039 0.1715
CV k2met 4% 6% 2% 7% 11% 6% 3% 3% 4% 8% 5% 4%
Table 6.1: Results of estimation at ROI level of Model A for whole subjects
In Table 6.2 are displayed the Akaike indexes of the estimates of each
ROI, that must be interpreted in their absolute value.
AIC indexes are higher in rivas group, immediately followed by nomed
group and then contr and donep groups.
AIC contr03 contr05 donep02 donep04 nomed04 nomed08 rivas01 rivas07
ROI 1 2.1927 2.5462 -0.1557 -0.3525 0.6885 0.5575 0.8316 0.4387
ROI 2 -0.3077 0.4265 0.8992 0.2913 0.5073 -0.2980 0.2862 1.4294
ROI 3 0.1912 -0.0437 1.5888 0.2836 1.2575 0.1989 2.9737 0.7326
ROI 4 0.8319 0.1636 0.4422 -0.1385 1.3080 1.2946 1.7535 1.9286
ROI 5 0.2547 -0.1867 -0.2222 -0.7908 0.4187 1.5830 3.0792 1.0392
ROI 6 0.1745 0.0745 0.4549 -0.1083 0.5943 0.4019 2.3958 -0.2640
ROI 7 0.5926 0.7630 -0.4274 -0.2304 0.6254 2.0574 3.5846 0.8280
ROI 8 0.5820 0.5639 0.7480 -0.6470 0.9208 0.2050 3.1857 1.0587
ROI 9 0.5578 1.1495 -0.0847 -0.3118 0.8260 2.0858 3.3480 1.4620
ROI 10 0.3152 0.9013 0.0320 0.2549 0.5130 0.1686 2.6087 2.2570
ROI 11 0.2583 0.8551 1.3269 0.1344 0.5023 1.0435 0.4577 0.0835
ROI 12 0.4041 0.4436 0.3674 -0.2171 0.8256 1.0460 2.0033 0.7508
Table 6.2: AIC indexes of the 12 ROIs for the estimation of Model A for all subjects52 6.2 Model B
6.2 Model B
Structure of Model B requires the parameters K1, k2, k1met and k2met to
be estimated:







The Table 6.3 shows the parameters values and their related Coe￿cient
of Variation in the 12 ROIs for the 8 subjects.
In 21% of cases Vb cannot be considered valid, because the software does
not lead to a successful result or because its estimated CV are higher than
100%. For the whole group, Vb in Region of Interest 1 is very low.
Subject ROI 1 ROI 2 ROI 3 ROI 4 ROI 5 ROI 6 ROI 7 ROI 8 ROI 9 ROI 10 ROI 11 ROI 12
contr03
Vb - 0.0072 0.0233 0.0269 0.0314 0.0031 0.0036 - 0.0162 0.0430 0.0235 0.0229
CV Vb 13% 32% 48% 17% 37% 198% 14% 17% 19% -
k1 - 0.2767 0.2697 0.0906 0.2609 0.4443 0.8517 0.7996 0.5449 0.1790 0.3921 0.0953
CV k1 2% 12% 13% 7% 1% 3% 4% 2% 16% 6% 11%
k2 - 0.0105 0.0009 - 0.0092 0.0100 0.0033 0.0016 0.0091 0.0050 0.0058 -
CV k2 3% 210% 14% 2% 19% 51% 4% 51% 17%
k1met - 0.0262 0.3550 0.5407 0.1427 0.0291 0.3634 0.4958 0.0849 0.2607 0.2091 0.4053
CV k1met 5% 2% 3% 4% 6% 2% 2% 3% 3% 2% 2%
k2met - 0.3620 0.2728 0.3338 0.3471 0.3594 0.3606 0.3804 0.2763 0.2969 0.2512 0.3011
CV k2met 7% 4% 3 % 6% 9% 4% 4% 5% 5% 4% 3%
contr05
Vb - 0.0151 0.0211 0.0134 0.0242 0.0147 0.0204 - - 0.0031 0.0051 0.0271
CV Vb 10 % 10 % 11% 8% 9% 26 % 124% 107% 8%
k1 0.0729 0.1712 0.0413 0.1488 0.0388 0.1310 0.0718 0.0646 0.4191 0.3757 0.1168 0.0878
CV k1 10% 3 % 15 % 4% 16 % 4% 23 % 17% 3% 3% 9% 6%
k2 0.0082 0.0048 0.0003 0.0036 0.0026 0.0039 0.0119 0.0052 0.0015 0.0020 0.0013 0.0080
CV k2 16% 9 % 747 % 15% 86 % 14 % 25 % 51% 37% 24% 125% 12%
k1met 0.1830 0.0737 0.3541 0.2387 0.2790 0.1735 0.0242 0.0172 0.2872 0.2285 0.0326 0.0964
CV k1met 1% 2% 1% 1% 1% 1% 21% 21% 2% 2% 24% 2%
k2met 0.1921 0.2043 0.1953 0.1839 0.1825 0.1769 0.2141 0.2192 0.2666 0.2510 0.3321 0.2304
CV k2met 2% 4% 1% 1% 1% 2% 40% 38% 4% 4% 39% 4%
donep02
Vb - 0.0070 - - 0.0124 0.0190 0.0131 0.0086 0.0050 0.0242 0.0036 0.0059
CV Vb 95% 14 % 24% 16% 67% 17% 13% 298% 62%
k1 0.0720 0.0332 0.1273 0.2798 0.0867 0.0261 0.0437 0.0615 0.1046 0.0440 0.0428 0.0830
CV k1 2% 9 % 5 % 4 % 8% 8 % 17% 24 % 3% 17% 11% 3%
k2 - - - 0.0008 0.0038 - 0.0059 0.0117 0.0088 0.0037 - -
CV k2 78 % 33% 41 % 34 % 5% 72%
k1met 0.1970 0.3252 0.5105 0.3023 0.1137 0.2353 0.0278 0.0293 0.0313 0.1112 0.4341 0.2881
CV k1met 1 % 2% 3% 1% 2% 2% 7% 23% 3% 3% 3% 1%
k2met 0.1708 0.2268 0.2582 0.2428 0.1759 0.2234 0.1673 0.2687 0.2320 0.2177 0.2480 0.1986
CV k2met 1% 3% 4% 3% 3% 2% 12% 44% 6% 5% 4% 2%
donep04
Vb - 0.0290 0.0055 0.0070 0.0108 0.0127 0.0185 0.0087 0.0029 0.0184 0.0113 0.0003
CV Vb 14% 74% 38% 12 % 19% 14 % 16% 43% 18% 37% 3133%
k1 0.0873 0.0574 0.1510 0.1794 0.0907 0.0685 0.0589 0.1044 0.0720 0.0636 0.0195 0.0072
CV k1 5 % 20% 2% 4% 1% 2 % 12 % 5% 6% 14% 48% 288%
k2 0.0058 0.0073 - 0.0005 - - 0.0006 0.0020 0.0092 0.0145 0.0089 0.0165
CV k2 10 % 35% 117% 298% 36% 8% 11% 72% 394%
k1met 0.0801 0.1631 0.4040 0.2833 0.2297 0.3405 0.2412 0.1379 0.0242 0.0777 0.0410 0.0033
CV k1met 2% 3% 1% 1% 1% 1% 1% 1% 7% 5% 11% 200%
k2met 0.1826 0.2100 0.2298 0.2083 0.1812 0.2208 0.2021 0.1683 0.2082 0.2386 0.2384 0.3283
CV k2met 3% 5% 2% 2% 1% 1% 2% 2% 12% 9% 21% -
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Subject ROI 1 ROI 2 ROI 3 ROI 4 ROI 5 ROI 6 ROI 7 ROI 8 ROI 9 ROI 10 ROI 11 ROI 12
nomed04
Vb - 0.0449 0.0282 0.0196 0.0142 0.0381 - 0.0194 0.0297 0.0343 0.0381 0.0318
CV Vb 7% 22 % 33% 10% 6% 32% 12% % 16% 10% 9%
k1 0.1151 0.0495 0.2561 0.2581 0.1020 0.0697 0.0686 0.0707 0.1174 0.0257 0.0453 0.1301
CV k1 5 % 15% 4 % 4% 3% 6% 25% 10% 7% 39% 22% 6%
k2 0.0122 0.0238 0.0058 0.0058 0.0118 0.0176 0.0118 0.0154 0.0104 0.0107 0.0222 0.0119
CV k2 7 % 8% 14 % 13% 5 % 5 % 31% 13% 11% 60% 14% 7%
k1met 0.1464 0.2967 0.3768 0.4889 0.0483 0.1473 0.0192 0.0608 0.3497 0.5276 0.4070 0.2376
CV k1met 2% 1% 2% 2% 3% 2% 28% 21% 1% 1% 1% 1%
k2met 0.2469 0.2897 0.3040 0.3337 0.2774 0.3133 0.2131 0.5214 0.2588 0.2941 0.2839 0.2419
CV k2met 3% 2% 4% 3% 6% 3% 46% 25% 2% 2% 2% 2%
nomed08
Vb - 0.0092 0.0247 0.0454 0.0617 0.0343 0.0489 0.0404 0.0554 0.0474 0.0585 0.0561
CV Vb 23% 16 % 23 % 6% 14% 9% 9% 9% 10% 8% 10%
k1 0.1310 0.0766 0.1202 0.1720 0.2795 0.4030 1.3709 0.7882 1.6441 1.1252 1.2472 1.5132
CV k1 6 % 16 % 16% 15% 16% 7% 1% 2% 1% 1% 1% 1%
k2 0.0206 0.0105 0.0083 0.0315 0.1228 0.1254 0.1230 0.1078 0.1295 0.1152 0.1558 0.1705
CV k2 4 % 15 % 20 % 7 % 18% 20% 2% 7% 2% 5% 5% 4%
k1met 0.0591 0.0282 0.0589 0.1496 0.2069 0.0470 0.0217 0.0402 0.0299 0.0457 0.1025 0.1209
CV k1met 9% 10% 8% 10% 7% 20% 8% 13% 7% 10% 4% 3%
k2met 0.3803 0.1896 0.1999 0.3651 0.2212 0.0417 0.0145 0.0304 0.0183 0.0276 0.0383 0.0387
CV k2met 13% 15% 13% 15% 8% 22% 18% 16% 14% 13% 5% 4%
rivas01
Vb - 0.0082 0.0139 0.0214 - 0.0054 0.0012 0.0080 0.0050 0.0116 0.0140 0.0215
CV Vb 29 % 28% 12% 98% 380 % 38% 66% 21% 18% 22%
k1 0.0287 0.0535 0.2338 0.0831 0.5686 0.3438 0.4487 0.2998 0.3428 0.1750 0.0682 0.0853
CV k1 24 % 9% 2% 4% 6 % 10 % 1 % 1% 1% 2% 14% 5%
k2 0.0238 0.3578 0.1017 0.0488 0.2041 0.2092 0.1165 0.0897 0.1056 0.0622 0.2261 0.0780
CV k2 13 % 22% 2% 4% 2 % 4 % 2 % 2% 1% 3% 29% 6%
k1met 0.0983 0.0603 0.3117 0.2502 0.4036 0.4958 0.4889 0.3968 0.3793 0.3020 0.0859 0.2541
CV k1met 17% 10% 5% 3% 10% 8% 4% 3% 4% 2% 21% 6%
k2met 0.3472 0.0944 0.3644 0.2414 0.1477 0.1628 0.3785 0.2695 0.3564 0.2334 0.0846 0.3450
CV k2met 31% 9% 6% 4% 8% 7% 5% 4% 4% 4% 18% 8%
rivas07
Vb - 0.0322 0.0176 0.0256 0.0198 0.0090 0.0259 0.0252 0.0218 0.0209 0.0110 0.0258
CV Vb 13 % 13% 17 % 56 % 18 % 18 % 28% 16% 26% 16% 18%
k1 0.1674 0.1698 0.1719 0.2457 0.0515 0.0604 0.1553 0.1446 0.2073 0.3248 0.1149 0.1078
CV k1 6 % 7 % 8% 5% 44 % 9 % 12 % 16% 8% 4% 6% 11%
k2 0.0204 0.0455 0.0282 0.0570 0.0408 0.0180 0.0136 0.0164 0.0402 0.0665 0.0194 0.0320
CV k2 3 % 4% 2% 5 % 19 % 6 % 10 % 11% 4% 5% 3% 4%
k1met 0.0749 0.1721 0.1584 0.2454 0.0931 0.0299 0.3579 0.4753 0.2436 0.3236 0.0436 0.1187
CV k1met 5% 3% 3% 3% 18% 7% 2% 2% 2% 3% 6% 5%
k2met 0.1908 0.2271 0.1624 0.2209 0.3218 0.2205 0.1965 0.2193 0.1774 0.2343 0.2139 0.2771
CV k2met 8% 6% 4% 4% 29% 13% 3% 4% 4% 4% 11% 9%
Table 6.3: Results of estimation at ROI level of Model B for whole subjects
Parameter k1 has always good estimates, in each ROI. For patient nomed08
it assumes very high values in Region of Interest 7, 9, 10, 11, 12.
k2 shows very low values in patients of contr and donep groups, and for
these subjects the percentage of non estimated, or with high CV, parameters
riches the 50% of values. In nomed and rivas groups, k2 assumes signi￿cant
values with good CV.
In Table 6.4 are displayed the Akaike indexes relative to estimates of
each ROI, that must be interpreted in their absolute value. AIC indexes
have nearly the same values in all subjects.
Comparing the Akaike indices of the two models we can see that, overall,
the values for Model B are 50% lower than those of model A and the di￿erence54 6.2 Model B
so marked is given by the indices of the rivas and nomed groups, extremely
high for the model A.
AIC contr03 contr05 donep02 donep04 nomed04 nomed08 rivas01 rivas07
ROI 1 -0.1025 -0.1084 -1.0531 -0.2970 -0.3282 0.7045 -0.3481
ROI2 -1.7925 -0.3851 0.9447 0.2193 -0.0960 -0.4262 -0.5062 1.4407
ROI 3 0.2305 0.0017 1.6342 0.3291 0.6779 0.0089 0.1883 -0.3511
ROI 4 0.8785 -0.3792 0.4422 -0.1121 0.6813 0.7704 -0.0948 0.2303
ROI 5 -0.2219 -0.1732 -0.3411 -0.7456 -0.7868 -0.0900 0.7048 0.9710
ROI 6 -1.3947 -0.4547 0.5003 -0.1998 -0.5154 0.1807 0.4886 -0.7858
ROI 7 0.2048 0.7501 -0.4821 -0.1886 0.5715 -0.0088 0.3572 0.3562
ROI 8 0.5339 0.5422 0.7363 -0.7686 0.4475 -0.0559 0.0632 0.6254
ROI 9 -0.7915 1.0231 -1.1487 -0.9360 0.1622 0.1476 0.0451 0.0581
ROI 10 0.2847 0.6077 0.0358 -0.0996 0.4949 0.1128 -0.0357 0.4364
ROI 11 -0.1355 0.8783 1.3724 0.1468 0.1760 0.3000 -0.1502 -0.6540
ROI 12 0.4496 -0.1253 0.4128 -0.1732 -0.0912 0.2647 0.3647 0.1472
Table 6.4: AIC indexes of the 12 ROIs for the estimation of Model B for all subjectsChapter 7
Results: Voxel - based
quanti￿cation method
The voxel-based quanti￿cation process main advantage is to maintain the
original resolution of the PET images during the evaluation of parameters.
By the way, the disadvantages are not negligible: ￿rst of all the signal-noise
ratio (SNR) is worse than that measured for the ROI and then, having a lot
of data to be analyzed, it is necessary to use fast algorithm for their iden-
ti￿cation. The gold-standard quanti￿cation method, Weighted Non Linear
Least Square, it’s not applicable in this context because the computational
burden would require processing time clinically unacceptable.
The Basis Function Method stands as an alternative to a non-linear quan-
ti￿cation method. As we described on Chapter 4, this method switches from
a nonlinear parameter dependence to a linear parameter dependence model.
The equations of our two models both have one or two parameters related
to the kinetics with a non-linear relationship.
Model A:


























For those non-linear components, next step will be the evaluation of the
Basis Functions through which we will provide the parameters estimates
using Linear Least Squares.56 7.1 Parameters grids
7.1 Parameters grids
The development of the Basis Function starts from the construction of the
grids for the parameters k2 and k2met. This is the most delicate step of
the whole procedure and what is the most appropriate grid is still an open
question that must be evaluated case by case. During the construction phase
of the grids we must take into account two critical issues: the number of
elements of the grid, which is closely related to the computational burden
of the algorithm and the accuracy of the ￿nal estimates, and the upper and
lower extremes of the grid within which it makes sense to assume that the
parameter can take value.
Starting from two di￿erent model structures, that requires di￿erent fea-
tures, we have chosen to split the problem in a way to create ad hoc grids
for each of the two cases in analysis.
7.1.1 Model A: k2met parameter grid
The application of the BFM to Model A, having this model a unique non-
linear component to elude, requires a computational burden linearly propor-
tional to the number of elements of the grids. We chose to dimension the
grid with N = 300 elements, a fairly large number, which will allow us a
good accuracy in the precision of the estimates. The range of values of the
grid must be chosen in order to cover all the possible values that the pa-
rameter could assume. Based on the results obtained from ROI-level k2met
estimates, we decided to ￿x the lower edge to 0 and the upper edge to 1.
Grid was developed in MATLAB :
%Construction of k2_met grid from 0 to 1, N=300
grid=logspace(log10(0.008),log10(1),299)’;
k2met_gridA(:,1)=[0; grid];
Results from ROI-based quanti￿cation return that a little less than 50% of
values were included from 0 and 0.2 , another little less than 50% of values
were included from 0.2 and 0.5 and the remaining 1% of values was higher
than 0.5. Therefore, we chose a distribution of logarithmic type in order to
have elements more dense at lower values and elements more widely spaced
at higher values, as we can see in Table 7.1: the more the value is high the
more the gap from previous element is big.
value 0 0.0126 0.0205 0.0333 0.0541 0.0880 0.1431 0.2327 0.3783 0.6150 1
index 1 30 60 90 120 150 180 210 240 270 300
Table 7.1: Grid of k2met values taken 1 every 30
7.1.2 Model B: k2 and k2met parameters grids
The construction of parametric grids for Model B required a more delicate
process. The structure of the model provides, in fact, two parameters with
non-linear dependence, this implies that if each grid is composed of M values,
the number of iterations that the algorithm will have to make are at least M7.1 Parameters grids 57
x M. At this point, it becomes crucial to ease the burden of the algorithm
building grids with a contained number of elements. However, it is equally
important that the grids could be able to adequately describe all the possible
values that the parameters could take.
We decided to act through two di￿erent paths: the ￿rst provided that
the grids were structured with a few values wisely chosen from previous
quanti￿cations at ROI-level, and the second sacri￿ced the burden of the
algorithm in favor of a wider description of the range of possible values.
ROI grids
Starting from the estimates obtained from the cluster analysis we developped
the grids for the parameters k2 and k2met. The ￿rst set of grids was con-
structed for each ROI of each patient, while the second was constructed from
the average of the values of the 12 ROIs of each patient, both in terms of
value of the parameter and in terms of CV. In the following we will describe
how both groups of grids were built.
Grids constructed on each ROI In order to contain the burden of the
algorithm we chose to size grids of k2 and k2met both with 20 values
each, suitably constructed on the basis of ROI-level quanti￿cation.
Figure 7.1: Example of development of a grid for parameters k2 and k2met from
ROI 1 for patient nomed04
For each subject and for each ROI we took the estimated value and the
Coe￿cient of Variance obtained from ROI-based estimation and we get
the relative Standard Deviation. We derived the lower and upper limits
of the range as [ROIvalue  2SD] and we divided it into 20 equally
spaced elements (Figure 7.1).
Grid constructed on ROIs mean For each subject we calculated the re-
lated grid through the average of the 12 parameters values of the 12
ROIs. Upper and lower extremes were calculated by adding 3meanSD58 7.2 Model A
and subtracting 3meanSD from the average value already found: [meanROIvalue
3meanSD]. The meanSD was in turn calculated as the mean of the
12 Standard Deviations of each ROI for the parameter in exam.
In this case we chose to size both grids with 30 elements each, consider-
ing that the range values would be more extended than in the previous
case, but trying anyway not to burden the algorithm.
Extended grids
The extended grids are constructed as an alternative to those developed on
ROI. These grids, in fact, sacri￿ce the computational burden for greater
accuracy in the estimates. Each grid is composed of 90 elements spacing
between a wide range.
The same grid, covering a large range of values, was used to calculate the
Basis Functions indistinctly for each ROI and for each patient.
7.2 Model A
The development of Basis Functions, once you have the parameters grids,
is the next step. In the case of Model A, the functions to be estimated are
those derived from the portion of non-linear kinetics for the parameter k2met.
Considering that the grid has N=300 elements, the Basis Function for the
i-th element of the grid has the form:
BFi(t) = Cmet(t) 
 e (k2met)it i = 1;:::;N
and, always for the i-th element, the equations of the predicting model be-
comes:
CV OI(t) = (1   Vb)(k1
Z t
0
Cp(t) + k1metBFi(t)) + VbCb







































The equation that relates the three components is:
Cpred = Aipar
And through the Weighted Linear Least Square we achieve the parameters
estimation:
^ par = [AT
i WAi] 1AT
i WCpred7.2 Model A 59
where the W = diag(w) 2 <MxM is the diagonal matrix of weight
described further.
The procedure is as follows:
For i = 1;:::;N












k=1 wkk[CV OI(tk)   Cpred(tk)]2
end




^ ((1   Vb)k1)i





The data weight was managed through the relative weights. The use of
relative weights instead of absolute ones, did not a￿ect the estimation of the
parameters, however it was important to get the absolute weights to know the
precision of the estimates. Since these weights were unknown, we proceeded
in this way:
1. We build the diagonal matrix of the weight on centroids values:
Sigma=diag(sqrt(mean_centroids./scan_sec));
2. Negative values have been imposed with zero weight:
inv_Sigma=(Sigma)^-1;
inv_Sigma(find(Cvoi<0),find(Cvoi<0))=0;
3. Estimates where then calculate through WLLS






where the GGi corresponds to the previously de￿ned Ai at optimal
index60 7.2 Model A
7.2.1 Results Model A
We applied the Basis Functions Methods at Model A for each patient.
For what concern the statistics of the obtained results, we evaluated the
number of acceptable estimations and for the valid ones we calculated the
mean value, the maximum and the minimum, of parameters Vb, k1 and k1met.
For the statistic of parameter Weighted Residuals Sum Squares (WRSS) we
only evaluated the mean value.
In Table 7.2 are shown the results for each subject, ￿elds Estimates
TOT and Estimates valid represent the number of estimations that the
program calculated and the number of which we considered valid in terms of
physiologically acceptable values (non negative) and statistic variance (CV
< 200%).











mean 0.1988 0.2271 0.0803 159 93135 111932 69123 117233 54293
max 12.102 0.9229 0.4934
min 0.0024 0.0003 0.0086
contr05
mean 0.0777 0.1499 0.0449 328 76121 102850 79611 107083 53057
max 0.5467 0.7834 0.3797
min 0.0018 0.0002 0.0031
donep02
mean 0.0567 0.1557 0.05 311 91042 124135 96910 129578 62940
max 0.4161 0.8316 0.5209
min 0.0019 0.0002 0.0028
donep04
mean 0.0626 0.1634 0.0479 200 74527 98832 81286 106335 55514
max 1.022 65.683 1.3932
min 0.0004 0.0002 0.002
nomed04
mean 0.0537 0.2018 0.0528 278 80086 118402 96771 121078 61482
max 0.3443 0.8822 0.4852
min 0.0026 0.0004 0.0029
nomed08
mean 0.0928 0.1683 0.0622 163 42817 93733 73612 101674 27156
max 0.5439 0.9787 0.386
min 0.0017 0.0003 0.0045
rivas01
mean 0.0235 0.1143 0.0408 238 3925 104231 113527 123675 3203
max 0.0681 0.9568 0.289
min 0.0032 0.0002 0.0019
rivas07
mean 0.0389 0.1524 0.0432 176 40273 100755 77465 111112 25090
max 0.2058 0.6327 0.3887
min 0.0037 0.0008 0.0032
Table 7.2: Statistics of the estimated parameters for Model A7.2 Model A 61
At least half of the estimates are not acceptable. In particular for patients
treated with rivastigmine percentage of acceptable estimates is extremely
lower than that of the estimates to reject. The drastic reduction in the
number of acceptable estimates is, as can be noted, due to the di￿culty of
estimating the parameter k1, particularly for patients in the group of nomed
and rivas. To report the maximum value of k1met of subject donep04 ab-
solutely in contrast with the habitual values of kinetic parameters, probably
an outlier.
In the next pages are reported the histograms of the distribution of the
values of optimal k2met in each subject (Figure 7.2 ).
The distribution of the indices values shows that many of the optimal
k2met fall within the range [0.04 - 0.4] and another good part of them within
[0.025-0.035]. In particular, patients treated with rivastigmine manifest a
very high peak of optimal k2met on the lower values range, however the
majority of these values will not be taken into consideration by the program
because it will provide inconsistent estimates.
Kinetic cerebral trends of indices k1, k1met, k2met, Vb and V tmet, where
V tmet is the Distribution Volume of the metabolite, are shown in Figures
7.3, 7.4, 7.5 .
The free tracer and the metabolite enter the brain ￿rst from the area of
the cerebellum after which, while the metabolite di￿uses freely in all brain
areas, the tracer remains con￿ned within this zone. Figure 7.3 and Figure
7.4 show this behavior for the subjects in which the amount of acceptable
estimates allowed a qualitative and quantitative analysis of the performance
of the parameters: contr03, contr05, donep02, donep04.
In subjects from contr group the tracer can also spread in thalamic areas
while in those belonging to donep group the signal coming from thalamic
areas is very low and therefor not signi￿cative, as shown in Figure 7.5. As
previously said, the remaining groups are di￿cult to examine because valid
results are poor.
The metabolite presents signi￿cant k1met values in all brain regions and
moreover those values are proportional to the ones of k2met, therefore, in
turn, signi￿cant.
Consequently V tmet is uniform throughout the scalp. The values of Vb
are maintained for the most part within physiologically acceptable values for
all patients of which it is possible to provide a visual interpretation of the
performance.
These results are in agreement with those obtained from the ROI analysis
for the model A.
In subjects nomed04, nomed08, rivas01, rivas07 the number of accept-
able estimations was very low and it was not possible to make some consid-
erations about the kinetic trends of parameters.62 7.2 Model A
(a) k2met distribution for contr03. (b) k2met distribution for contr05.
(c) k2met distribution for donep02. (d) k2met distribution for donep04.
(e) k2met distribution for nomed04. (f) k2met distribution for nomed08.
(g) k2met distribution for rivas01. (h) k2met distribution for rivas07.
Figure 7.2: Histograms of distribution of k2met for all subjects7.2 Model A 63
(a) Parameter trends for contr03.
(b) Parameter trends for contr05.
Figure 7.3: Visualization of tracer trend in cerebellum for subject contr03 and
contr0564 7.2 Model A
(a) Parameters trends for donep02.
(b) Parameters trends for donep04.
Figure 7.4: Visualization of tracer trend in cerebellum for subject donep02 and
donep047.2 Model A 65
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
Figure 7.5: Visualization of tracer trend in thalamic areas for subject contr03 and
donep0266 7.3 Model A Bayesian estimation: MAP
7.3 Model A Bayesian estimation: MAP
We then applied the Bayesian approach for parameter estimation of the
Model A. The starting point of this approach is based on the fact that,
even before estimation of the parameters, we have expectations for them,
that is information, summarized in the a priori probability density:
fp(p)
These expectations are changed after seeing the data z, therefore we speak
of the a posteriori probability density, conditioned by z:
fpjz(pjz)
This is the function key of Bayesian estimation, from that we get estimates
and con￿dence intervals.
A Bayesian estimator is the Maximum a Posteriori (MAP).
De￿ned z the data, v weights matrix, G(p) the model matrix de￿ned
as Ai in Section 7.2, p the covariance matrix of the prior information and
eventually p the a priori information vector, the estimations were calculated
through:
^ pmap = (GTvG +  1
p )(GTvz +  1
p p)












k1prior(1   V bprior) k1metprior(1   V bprior) V bprior

We built our p and p through the results from ROI-based analysis and
then we applied the MAP Estimation to our data.
Summarizing, this method solves the compartmental model with the fol-
lowing procedure: model is linearized through the Basis Function Method
and then solved using a linear Maximum A Posteriori (MAP) estimator,
priors were previously automatically generated from the data, using the es-
timates obtained solving the compartmental model at the region level (func-
tional clustering).
7.3.1 Results MAP
Bayesian estimation has been applied only to model A, in order to see if, pro-
viding a prior information, the results of the estimation improved, especially
for those patients in which the valid estimates were few.
The overall results are given in Table 7.3. The number of valid estimates,
Estimates TOT, increased for all patients, especially for those in which we
found some di￿culties in the previous model. By the way, for subject rivas01
number of not acceptable estimates is nearly the 80%, and the parameter
whose estimation hardly depress this number is k1.7.3 Model A Bayesian estimation: MAP 67











mean 0.2065 0.3277 0.0733 234 97990 93515 45707 117233 43149
max 0.4912 0.6769 0.3779
min 0.0049 < 0:1e 006 0.0134
contr05
mean 0.1132 0.1628 0.0405 392 75657 74757 63222 107083 56445
max 0.557 0.749 0.2908
min 0.0029 < 0:1e 006 0.0048
donep02
mean 0.0995 0.1656 0.0418 382 99867 108099 86701 129578 72210
max 0.3772 0.7 0.5002
min 0.0059 < 0:1e 006 0.0047
donep04
mean 0.0991 0.1127 0.0425 227 93928 65932 78037 106335 73599
max 0.3373 0.6178 0.2533
min 0.0036 < 0:1e 006 0.0049
nomed04
mean 0.0913 0.2078 0.0518 345 100139 81569 94541 121078 88495
max 0.3031 0.8577 0.3531
min 0.002 < 0:1e 006 0.0036
nomed08
mean 0.1627 0.2283 0.0549 305 67417 83316 68094 101674 44333
max 0.5424 0.9782 0.2913
min 0.0089 < 0:1e 006 0.008
rivas01
mean 0.0409 0.1419 0.0424 499 26117 113382 115500 123675 24687
max 0.1291 0.8086 0.2755
min 0.0026 < 0:1e 006 0.0017
rivas07
mean 0.0925 0.1585 0.0417 249 79801 87454 81704 111112 67481
max 0.2061 0.6673 0.2465
min 0.0048 < 0:1e 006 0.0039
Table 7.3: Statistics of the MAP estimations of Model A68 7.3 Model A Bayesian estimation: MAP
Parameters values of k1, k1met and Vb are all within acceptable range.
WRSS are a little bit higher than in the previous model but this is a
standard result while performing Bayesian estimation.
Histograms of the distribution of k2met are shown in Figure 7.6.
(a) k2met distribution for contr03. (b) k2met distribution for contr05.
(c) k2met distribution for donep02. (d) k2met distribution for donep04.
(e) k2met distribution for nomed04. (f) k2met distribution for nomed08.
(g) k2met distribution for rivas01. (h) k2met distribution for rivas07.
Figure 7.6: Histograms of distribution of k2met for all subjects with MAP estima-
tor
The distribution of the parameters is much more homogeneous than in the7.3 Model A Bayesian estimation: MAP 69
analysis without prior. Moreover, the peak values that occurred at around
the 100-th index appears now much reduced and in some subjects, even not
visible.
These ￿ndings have their feedback when we analyze PET images. In
Figure 7.7 and in Figure 7.8 are shown results from contr03 and donep02
to give visually con￿rm to what we said about the homogeneity of the found
parameters: images appears smoother and anatomical distinct regions are
more visible.
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
Figure 7.7: Visualization of smoother tracer trends for subject contr03 and
donep02 from MAP estimation. Focus on cerebellum area70 7.3 Model A Bayesian estimation: MAP
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
Figure 7.8: Visualization of smoother tracer trends for subject contr03 and
donep02 and from MAP estimation. Focus on thalamic areas7.3 Model A Bayesian estimation: MAP 71
While analyzing those patients which couldn’t a￿ord good estimates in
the previous quanti￿cation, we can see a great improvement in the quality
of the results. By visual inspection it is now possible to evaluate that even
in subjects of nomed group there is a localized di￿usion of the tracer in the
cerebellum and in the thalamic areas, while the metabolite freely di￿uses in
the whole brain (Figure 7.9, 7.10). For what concern rivas07, cerebellum
and thalamic activity of parameter k1 are not so evident, while they shows
high values for k1met that it seems to spread mainly in those areas.
As we said previously, subject rivas01 didn’t provide good estimates, and
the number of valid ones was so low that we couldn’t make any considerations
about its kinetics.
(a) Parameters trends for nomed04.
(b) Parameters trends for rivas07.
Figure 7.9: Visualization of smoother tracer trends for subject nomed04 and ri-
vas07 and from MAP estimation. Focus on cerebellum.72 7.3 Model A Bayesian estimation: MAP
(a) Parameters trends for nomed04.
(b) Parameters trends for rivas07.
Figure 7.10: Visualization of smoother tracer trends for subject nomed04 and ri-
vas07 and from MAP estimation. Focus on thalamic areas7.4 Model B 73
7.4 Model B
In the case of Model B, the functions to be estimated are those derived
from the two portions of non-linear kinetics for the parameters k2 and k2met.
Considering that the grids have both N=20 or N=30 or N=90 elements,
depending on the case, the Basis Function for the i-th element of the grid
has always the form:
BFk2i(t) = Cp(t) 
 e (k2)it i = 1;:::;N
BFk2metj(t) = Cmet(t) 
 e (k2met)jt j = 1;:::;N
and, always for the i-th element, the equations of the predicting model be-
comes:
CV OI(t) = (1   Vb)(k1BFk2i(t) + k1metBFk2metj(t)) + VbCb






































The equation that relates the three components is:
Cpred = Aijpar
And through the Weighted Linear Least Square we achieve the parameters
estimation:
^ par = [AT
ijWAij] 1AT
ijWCpred
where the W = diag(w) 2 <MxM is the diagonal matrix of weight described
further.
The procedure is as follows:
For i = 1;:::;N
for j = 1;:::;N
k2met = (k2met)i ; BFk2met = BFk2meti











k=1 wkk[Cvoiij(tk)   Cpredij(tk)]2
end
end74 7.4 Model B




^ ((1   Vb)k1)ij





Data weight was managed through the relative weights as for Model A.
The estimation was performed using the relative weights, de￿ned by:
Sigma=diag(sqrt(mean_centroids./scan_sec));
while the absolute weights were calculated only "a posteriori" and used to
provide the actual precision of the estimates.
7.4.1 Results for grid built on each ROI
We applied BFM at Model B using the grid built on each ROI and we ana-
lyzed the results as for Model A.
Table 7.4 shows the estimations of k1, k1met and Vb maximum and
minimum values in addition to the average. Weighted Residuals Sum Squares
is also reported to allow a comparison with the related values of following
models. Number of estimates Estimates TOT and number of acceptable
estimates Estimates valid were calculated in order to understand how many
values have been deleted or because in contrast with physiological acceptable
values or because the estimation had a CV higher than 200%.
For what concern this latest parameter, Estimates valid, we can see that
in rivas group it is very low. In rivas01 only the 22% of values is taken in
consideration and in rivas07 the 27%, while in other subjects the percentage
of valid estimation is always higher than 45%, reaching 63% in donep04.
Parameter that seems more di￿cult to estimate is Vb, it’s the one with the
least number of valid values. In rivas01 the value of valid estimates of k1
it’s very low too.
By the way, comparing these results with those of Model A, Table 7.2,
the acceptable estimates are globally higher in Model B, for each patient.
Results for k1, k1met and Vb are in line with the values obtained for these
parameters from other kinetic tracer analyzing models available in literature.
The histograms of the distribution of k2 and k2met values are shown in
Figure 7.11 and in Figure 7.12.
The distribution of the values of k2met tends to concentrate to the extreme
bound of the interval, in particular for patients rivas01 and rivas07 and the
percentage of values falling in the central part of the interval is very low. This
behavior is accentuated even more for the distributions of the parameter k2,
where it seems that the histogram try to overcome the edge of the range.
It’s still not clear if the edge values are those that are deleted at a later
time, by the way it could be signi￿cative to enlarge the range of parameters
k2 and k2met to evaluate if this trend might change (Subsection 7.4.2).7.4 Model B 75











mean 0.3204 0.2068 0.0791 101 79685 74556 54060 117233 52217
max 1.4249 0.7419 0.4919 -
min 0.0071 0.0008 0.0127 -
contr05
mean 0.1065 0.1408 0.0443 166 71175 71834 60862 107083 57347
max 0.7119 0.7432 0.3748 -
min 0.0037 0.0030 0.0030 -
donep02
mean 0.0850 0.1354 0.0549 127 81566 81738 74244 129578 68197
max 0.5108 0.6457 0.3912 -
min 0.0027 0.0036 0.0035 -
donep04
mean 0.0866 0.1289 0.0496 129 77149 76273 70177 106335 67203
max 0.4755 0.5340 0.2980 -
min 0.0060 0.0072 0.0028 -
nomed04
mean 0.1028 0.1950 0.0526 133 80697 83451 75179 121078 68222
max 0.7858 0.9451 0.3427 -
min 0.0059 0.0056 0.0047 -
nomed08
mean 0.519 0.0573 0.0689 100 68081 60628 47068 101674 45271
max 2.3013 0.8576 0.3899 -
min 0.0008 0.0806 0.0082 -
rivas01
mean 0.203 0.2104 0.0771 203 37636 55285 45039 123675 28083
max 0.9059 1.3403 0.3645 -
min 0.0106 0.0215 0.0032 -
rivas07
mean 0.1341 0.1027 0.0522 115 59904 68563 32926 111112 29461
max 0.8014 0.6945 0.2833 -
min 0.0061 0.0009 0.0053 -
Table 7.4: Statistics of the estimations: Model B, grids built on each ROI76 7.4 Model B
(a) k2met distribution for contr03. (b) k2met distribution for contr05.
(c) k2met distribution for donep02. (d) k2met distribution for donep04.
(e) k2met distribution for nomed04. (f) k2met distribution for nomed08.
(g) k2met distribution for rivas01. (h) k2met distribution for rivas07.
Figure 7.11: Histograms of distribution of k2met for all subjects7.4 Model B 77
(a) k2 distribution for contr03. (b) k2 distribution for contr05.
(c) k2 distribution for donep02. (d) k2 distribution for donep04.
(e) k2 distribution for nomed04. (f) k2 distribution for nomed08.
(g) k2 distribution for rivas01. (h) k2 distribution for rivas07.
Figure 7.12: Histograms of distribution of k2 for all subjects78 7.4 Model B
Kinetic cerebral trends of indices k1, k1met, k2, k2met, Vb and V tmet,
where V tmet and Vt are the Distribution Volume of, respectively, the metabo-
lite and the tracer, are shown in the following ￿gures.
As regards the vascular volume presence, Vb this always takes values
within a rage of eligibility.
The Distribution Volume of the metabolite, V tmet assumes values be-
tween 1[%] and 5[%], homogeneously distributed within the whole brain vol-
ume.
The Distribution Volume of the tracer, Vt, has a very unbalanced dis-
tribution, in correspondence with the area of the cerebellum values touch
peaks between 50[%] and 200[%], and, except for donep group and subject
nomed04 that show high values also in correspondence of thalamic areas, the
remaining parts of the brain assume very low Distribution Volume values.
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
Figure 7.13: Visualization of tracer trend in cerebellum for subject contr03 and in
thalamic areas for donep02 from results of Model B analysis on ROI
grids7.4 Model B 79
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
(c) Parameters trends for nomed04.
Figure 7.14: Visualization of tracer trend in cerebellum for subject contr03,
donep02 and nomed04 from results of Model B analysis based on
ROI grids80 7.4 Model B
(a) Parameters trends for donep02.
(b) Parameters trends for donep04.
(c) Parameters trends for nomed04.
Figure 7.15: Visualization of tracer trend in thalamic area for subject contr03,
donep02 and nomed04 from results of Model B analysis based on
ROI grids7.4 Model B 81
For what concern k1, k2, k1met and k2met parameters, results are shown
in Figure 7.14 .
In patients of contr and donep groups the behavior of the parameters is
very similar.
Parameter k1 is maintained, with even higher values, within speci￿c re-
gions, particularly in the cerebellum for the control subjects, moving even
in the thalamic areas, clearly visible in the results of donep patients. In the
group of nomed and rivas only subject nomed04 presents estimates appre-
ciable and behaviour similar to donep patients.
Parameter k2 shows low values for all the patients examined.
Parameter k1met spreads initially in the area of the cerebellum, then
enters freely within the entire brain.
Parameter k2met is homogeneous throughout the brain and with reason-
able values.
In patients from rivas group and subject nomed08 is not possible to an-
alyze qualitatively and/or quantitatively the results because, as for previous
models, images are still not appreciable because of the lack of valid data.
7.4.2 Results for grid built on ROIs mean
Starting from the considerations that had been made for grids built on each
ROI we developed new grids, based on ROI analysis too, but evaluated on
the mean of ROIs values and enlarged until 3SD on the extremes. In Table
7.4 the results for each subject.
Fields Estimates TOT and Estimates valid represent the number of
estimations that the program calculated and the number of which we consid-
ered valid in terms of physiologically acceptable values and statistic variance
(CV < 200%).
In this case the value of EstimatesV alid is quite homogeneous for all
subjects without much di￿erences: contr, donep, nomed groups and rivas07
percentage of valid estimates is largely upper than 50%, the only subject
whose percentage is inferior at 50% is rivas01 reaching just the 40% of ac-
ceptable estimates.
Parameters k1, k1met and Vb Coe￿cients of Variance are for the major
part under the threshold value of 200%. The most problematic parameter to
estimate is, even in that case, Vb.
Comparing the number of valid estimates with the ones obtained from
previous results we can see that this value is higher than the value obtained
for Model A and for Model B using the grid built on each ROI.
Parameter WRSS is higher than the one of results obtained from Model
B using grid built on each ROI.
The histograms of the distribution of k2 and k2met values are shown
in Figure 7.11 and the tracer and metabolite kinetics trends are shown
immediately after.82 7.4 Model B











mean 0.3192 0.1823 0.0800 162 100926 88076 63360 117233 61889
max 2.0989 0.5299 0.4936
min 0.0033 0.0066 0.0095
contr05
mean 0.1012 0.1073 0.0471 340 90844 84682 78095 107083 71493
max 0.5975 0.6952 0.3756
min 0.0014 0.0023 0.0031
donep02
mean 0.0805 0.1150 0.0537 328 106366 99865 95947 129578 88664
max 0.5417 0.7535 0.4291
min 0.0018 0.0129 0.0034
donep04
mean 0.0917 0.1165 0.0502 208 88716 76775 75432 106335 72158
max 3.3193 11.3965 1.0104
min 0.0004 0.0002 0.0216
nomed04
mean 0.0909 0.1598 0.0531 269 94798 98405 93028 121078 79711
max 0.6557 0.8260 0.3690
min 0.0014 0.0014 0.0030
nomed08
mean 0.5814 0.0658 0.0748 169 96254 72011 73400 101674 70392
max 3.1622 0.5161 0.3917
min 0.0018 0.1957 0.0071
rivas01
mean 0.2156 0.1928 0.0534 363 79087 99672 78325 123675 51391
max 1.1449 1.2501 0.3677
min 0.0023 0.0004 0.0019
rivas07
mean 0.1511 0.1050 0.0511 176 94621 78143 62752 111112 59600
max 1.0323 0.6851 0.3696
min 0.0015 0.0001 0.0033
Table 7.5: Statistics of the estimations: Model B, grids built on ROIs mean7.4 Model B 83
Parameter values seem to distribute a little more homogeneously on the
interval. By the way it still remains the trend to exceed the upper and the
lower limit of the range, in particular the parameter k2 seems to have the
tendency to distribute nearly the upper edge of the interval.
(a) k2met distribution for contr03. (b) k2met distribution for contr05.
(c) k2met distribution for donep02. (d) k2met distribution for donep04.
(e) k2met distribution for nomed04. (f) k2met distribution for nomed08.
(g) k2met distribution for rivas01. (h) k2met distribution for rivas07.
Figure 7.16: Histograms of distribution of k2met for all subjects84 7.4 Model B
(a) k2 distribution for contr03. (b) k2 distribution for contr05.
(c) k2 distribution for donep02. (d) k2 distribution for donep04.
(e) k2 distribution for nomed04. (f) k2 distribution for nomed08.
(g) k2 distribution for rivas01. (h) k2 distribution for rivas07.
Figure 7.17: Histograms of distribution of k2 for all subjects7.4 Model B 85
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
(c) Parameters trends for nomed04.
Figure 7.18: Visualization of tracer and metabolite trends in cerebellum area for
subject contr03, donep02 and nomed04 from results of Model B anal-
ysis based on ROI means grids86 7.4 Model B
(a) Parameters trends for contr03.
(b) Parameters trends for donep02.
(c) Parameters trends for nomed04.
Figure 7.19: Visualization of Vt, V tmet and Vb trends in cerebellum area for subject
contr03, donep02 and nomed04 from results of Model B analysis based
on ROI means grids7.4 Model B 87
(a) Parameters trends for nomed08.
(b) Parameters trends for rivas01.
(c) Parameters trends for rivas07.
Figure 7.20: Visualization of tracer and metabolite trends for subject nomed08,
rivas01 and rivas07 from results of Model B analysis based on ROI
means grids88 7.4 Model B
(a) Parameters trends for nomed08.
(b) Parameters trends for rivas01.
(c) Parameters trends for rivas07.
Figure 7.21: Visualization of Vt, V tmet and Vb trends for subject nomed08, rivas01
and rivas07 from results of Model B analysis based on ROI means
grids7.4 Model B 89
For subjects of contr and donep groups and for nomed04 the trends of
parameters are very similar to the ones obtained from previous model. That
means the tracer enters mainly in cerebellum and thalamic areas but doesn’t
spread in the other regions: k1 is very high in that regions and very low
elsewhere. The metabolite, instead, di￿uses in the whole brain: k1met has
signi￿cant values everywhere (Figure 7.18).
For the same patients, also, Distribution Volume of tracer Vt shows high-
est peaks in cerebellum areas and very high values in thalamic zones while
the Distribution Volume of metabolite V tmet is quite constant in the whole
brain (Figure 7.19).
For what concern rivas group and nomed08 they seem to have a di￿erent
behaviour. That means that the k1 parameter associated to the kinetic of
the tracer indicates high values of di￿usion in the whole brain (especially for
nomed08), and the k2 values are, in those cases, relevant. Parameters that
describe the trends of the metabolite, k1met and k2met also di￿use in quite
the whole brain but with lower values (Figure 7.20). These results are in
agreement with those obtained from the ROI analysis for the model B.
Distribution Volume of tracer appears homogeneous, Vt values stay be-
tween 0[%] and 50[%], Distribution Volume of metabolite stays between 0[%]
and 5[%] (Figure 7.21).
7.4.3 Extended grids results
Starting from the consideration that it seemed that k2 and k2met had always
the tendency to distribute near the upper and lower values of the range, we
decided to built some extended grids, of 90 elements each. This solution had
been tested to understand if a wider range, with the increase of computational
burden that follows, could provide further information about which of the
two types of model better describes the data and about the trends of kinetic
parameters.
Analyzing the histogram of the distribution of values of k2 and k2met it
can be noted that there is always a tendency for a good portion of values to
accumulate near the extremes of the interval of the grid.
At visual inspection, from the obtained images of quanti￿cation of pa-
rameters, it is also possible to see that parameter k1 assumes very high values
anywhere within the section, both for patients in which the estimation had
encountered di￿culties for this parameter (rivas and nomed groups) and
in those in which the estimates were found to be good (contr and donep
groups).
The big di￿erence, in this case, is that for patients of rivas and nomed
groups we get a trend well distributed throughout the brain, while for sub-
jects contr and donep groups, the extremely high values of k1 are not con-
centrated in particular regions, but appear by way of salt and pepper noise
inside the brain (Figure 7.22).
Parameter k1met shows good estimations and in line with those obtained
from previous analysis, except for rivas group where high sporadic peaks of
values are present (Figure 7.22).
Distribution Volume of the tracer Vt shows the same noisy behaviour of k1
, with high peaks reaching values since 100[%] while the Distribution Volume90 7.4 Model B
of the metabolite V tmet is quite homogeneous in the whole brain and with
values between 0[%] and 5[%], except, of course, for patients rivas01 and
rivas07 (Figure 7.22).
(a) Parameters trends for contr03.
(b) Parameters trends for rivas01.
Figure 7.22: Visualization of di￿erent tracer trends for subject contr03 and rivas01
from BFM with Extended grids estimation. Subject contr03 shows
salt and pepper noise. Subject rivas01 shows good estimates and high
values of k1.Chapter 8
Conclusions
Recent ￿ndings have shown that the study of brain cholinergic system through
the instrument of PET with ad hoc synthesized tracers can be a valuable tool
for early diagnosis of Alzheimer’s disease. In particular, we wanted to study
the possibility of investigating for this purpose through a brand new tracer,
11C-MP4B, of which it still had not been developed any kinetic model for
quanti￿cation, and thus its e￿cacy had not yet been proven .
We started from the data of arterial sampling for 8 subjects, 2 controls
and 6 a￿ected from AD . The ￿rst step was to eliminate the noisy com-
ponents of the sampling in order to construct the functions, developed by
￿tting a model of exponential sums on the data, which acted as arterial
input functions of the kinetic model that we would develop later.
The ￿rst consideration that we made was about the trends of those arte-
rial sampling data. We noticed that for subjects of rivas and nomed groups
there was an irregularity, a sort of second peak of concentration that was
refered us as to be a noisy artifact. In light of the subsequent analyzes, that
have seen the patients of this groups form a sort of subgroup at the level
of the kinetic behavior, and in view of the fact that this false peak is not
manifested in the same way for all patients, leaving room for doubt that it
may be not a noisy artifact. This will certainly be a reason for further future
investigations.
We started the analysis of the images themselves and we decided, as a ￿rst
step, to begin our analysis by quantifying the cholinergic activity through a
region-based method rather then a voxel-based one. We performed then a
cluster analysis.
The algorithm was constructed so that it performed clustering on the
TACs suitably parameterized into 6 features. We got the division into 12 sub-
regions which in turn re￿ected some precise anatomical areas: cerebellum,
thalamus, hippocampus, etc etc. This leads us to conclude that at functional
level, di￿erent anatomical regions have di￿erent kinetic behavior.
We then skipped to the evaluation of parameters and we did it for two
model structures appropriately constructed on the basis of state of art of92
tracers kinetic models and on the basis of models already tested for tracers
with similar substrate.
Performing ROI-level quanti￿cation, the results of the kinetic parameters
show complementary behaviour between a ￿rst group composed by subjects
contr03, contr05, donep02 and donep04 and a second group composed by
rivas01, rivas07, nomed04 and nomed08. For the ￿rst group the most
suitable model resulted to be Model A, because of the higher valid values
and accuracy of estimates and the lower WRSS, while, for the same reasons,
for the second group resulted to be Model B.
Finally, the last and most complex step, it was that of quanti￿cation at
voxel-level. We performed it through Basis Function Method. This estima-
tion method requires that were linearized the components with a non-linear
dependence with the measure equation: for the parameters in question we
built speci￿c grids, for each element of the grid we calculated the related mea-
surement equation and we estimated the parameters, then ￿nally we choose
the combination of grids values that has provided the lowest WRSS.
The application of the BFM returned results from which we could draw
the following conclusions regarding the grids suitability and the best model
structure to be used.
In light of the number of valid estimates and the goodness of the estima-
tion, Model A is the most suitable model for the quanti￿cation of cholinergic
activity in subjects of contr and donep groups while for patients of nomed
and rivas groups it doesn’t a￿ord acceptable estimates.
Using a priori information improves the goodness of the estimation in
terms of estimates precision and number of valid estimates. In patients where
the quanti￿cation didn’t lead to a signi￿cant number of valid estimates, MAP
estimator allowed better performance. By the way subject rivas01 was still
problematic.
Bayesian estimator allow a more qualitative analysis thanks to the prior
vector which gives a preliminary partitioning of the image into sub-regions.
Model B seems to be the most suitable model for the quanti￿cation of
the activity of nomed and rivas groups, where k2 assumes signi￿cant values,
while for contr and donep ones the values of the estimated k2 were so low
that we can say it might not be necessary to include it in the model structure.
Eventually, even voxel-based analysis returned that for those latest subjects,
the most suitable model could be Model A.
The most suitable grids structure for parameter k2 and k2met is still an
open question. From the results obtained using three di￿erent types of grids,
we could evaluate that the extension of the grid, increasing however the
computational burden, can not signi￿catively a￿ect the improvement of the
estimate. In our case, in fact, the use of extended grids has given rise to
a kind of compensation of the algorithm, for all subjects, even if related to
di￿erent parameters. By the way, it is important to report the fact that only
with those Extended grids we succeeded good results for rivas01.93
Between the two grids built on ROI, the most suitable was the one built
on the average of the 12 ROIs values, because of a little bit higher number
of elements and of the wider range.
Finally, as regards the behavior of the tracer, we can draw the following
conclusions. 11C-MP4B has not provided the desired results, especially since,
in the majority of subjects analyzed, the tracer remains con￿ned in some
areas of the brain and does not di￿use freely.
Moreover, in those patients where k2 had very low values it seems there
is a trapping region where the tracer enters and cannot exit anymore.
Metabolite product, instead, di￿uses in the whole brain, with a good
estimated kinetics, without trapping zones. It could be a reason for new
studies the possibility to extract information on cholinergic activity from
metabolite product rather than from the tracer.94Bibliography
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